UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36007

PHYSICIANS REALTY TRUST

(Exact Name of Registrant as Specified in its Charter)


Maryland		46-2519850
(State of Organization)		(IRS Employer Identification No.)

309 N. Water Street, Suite 500		53202
Milwaukee,	Wisconsin
(Address of Principal Executive Offices)		(Zip Code)

(414) 367-5600

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, $0.01 par value per share

DOC

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The number of Physicians Realty Trust’s common shares outstanding as of October ~~26, 2022~~27, 2023 was ~~228,260,860.~~238,487,448.

PHYSICIANS REALTY TRUST

Quarterly Report on Form 10-Q

for the Quarter Ended September 30, ~~2022~~2023

Table of Contents


		Page Number
Part I	Financial Information

Item 1	Financial Statements (Unaudited)


	Consolidated Balance Sheets as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022	3
	Consolidated Statements of Income for the Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	4
	Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	5
	Consolidated Statements of Equity for the Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	6
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	8









	Notes to Consolidated Financial Statements	9

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2325
Item 3	Quantitative and Qualitative Disclosures About Market Risk	3638
Item 4	Controls and Procedures	3739

Part II	Other Information

Item 1	Legal Proceedings	3941
Item 1A	Risk Factors	3941
Item 2	Unregistered Sales of Equity Securities, ~~and~~ Use of Proceeds and Issuer Purchases of Equity Securities	3946
Item 5	Other Information	46
Item 6	Exhibits	4047

SIGNATURES		4148

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts may be forward-looking statements within the meaning of the federal securities laws. In particular, statements pertaining to our capital resources, property performance, and results of operations contain forward-looking statements. Likewise, all of our statements regarding anticipated growth in our funds from operations and anticipated market conditions, demographics, and results of operations are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believe,” “expect,” “outlook,” “continue,” “project,” “may,” “will,” “should,” “seek,” “approximately,” “intend,” “plan,” “pro forma,” “estimate,” or “anticipate” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans, expectations, or intentions.

These forward-looking statements reflect the views of our management regarding current expectations and projections about future events and are based on currently available information. These forward-looking statements are not guarantees of future performance and involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data, or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

•the unknown duration and economic, operational, and financial impacts of the global outbreak of a novel strain of the coronavirus and any variants that have emerged or that may emerge in the future, (the “COVID-19 pandemic”) and the actions taken by governmental authorities or others in connection with the COVID-19 pandemic will have on the Company’s business;

•general economic conditions, including inflation and recession;

•changes in our business or strategy;

•risks associated with the Company Merger and the Partnership Merger (each as defined below and collectively, the “Mergers”), including our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all, and unanticipated difficulties or expenditures relating to the Mergers, potential difficulties in employee retention as a result of the Mergers, the occurrence of any event, change or other circumstances that could give rise to the termination of the Mergers and the outcome of legal proceedings instituted against us, our trustees and others related to the Mergers;

•our ability to operate as a public company;

•adverse economic or real estate developments, either nationally or in the markets where our properties are located;

•our geographic concentration in Texas may cause us to be particularly exposed to downturns in the Texas economy or other changes in Texas market conditions;

•our concentration of investment in health care properties;

•the disruption of our business and the compromise of confidential information resulting from cybersecurity attacks, breaches, and other incidents;

•any adverse effects to the business, financial position, or results of operations of CommonSpirit Health (“CommonSpirit”), or one or more of the CommonSpirit-affiliated tenants, that impact the ability of CommonSpirit-affiliated tenants to pay us rent;

•the degree and nature of our competition;

•competition for investment opportunities;

•difficulties in identifying health care properties to acquire and completing acquisitions;

•risks related to development, redevelopment, or construction projects;

•changes in health care laws or government reimbursement rates;

•decreased rental rates or increased vacancy rates;

Table of Contents

•defaults on or non-renewal of leases by tenants;

•the potential impact of severe weather events and climate change;

•our failure to generate sufficient cash flows to, subject to the restrictions in the Merger Agreement (as defined below), service, ~~our indebtedness or to~~ pay down, or refinance our ~~indebtedness;~~indebtedness or make distributions on our common shares;

•fluctuations and increases in interest rates and operating costs;

•the availability, terms, and ~~deployment~~issuance of debt and equity capital, including our unsecured revolving credit ~~facility;~~

•~~our ability~~facility, in each case, subject to ~~make distributions on our common shares;~~the restrictions in the Merger Agreement;

•general volatility of the market price of our common shares;

•~~our increased vulnerability economically due to the concentration of our investments in health care properties;~~

•~~our geographic concentration in Texas causes us to be particularly exposed to downturns in the Texas economy or other changes in Texas market conditions;~~

•~~changes in our business or strategy;~~

•our dependence upon key personnel whose continued service is not guaranteed;

•our ability to identify, hire, and retain highly qualified personnel in the future;

•~~the degree and nature of our competition;~~

•changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates, taxation of real estate investment trusts (“REITs”), and similar matters;

•~~defaults on or non-renewal of leases by tenants;~~

•~~decreased rental rates or increased vacancy rates;~~

~~Table of Contents~~

•~~difficulties in identifying health care properties to acquire and completing acquisitions;~~

•~~competition for investment opportunities;~~

•any adverse effects to the business, financial position or results of operations of CommonSpirit Health, or one or more of the CommonSpirit Health-affiliated tenants, that impact the ability of CommonSpirit Health-affiliated tenants to pay us rent;

•the impact of our investments in joint ventures we have made and may make in the future;

•the financial condition and liquidity of, or disputes with, any joint venture and development partners with whom we may make co-investments in the future;

•~~the disruption of our business and the compromise of confidential information resulting from cybersecurity attacks, breaches, and other incidents;~~

•~~our ability to operate as a public company;~~

•changes in ~~health care laws~~governmental regulations or ~~government reimbursement rates;~~

•~~changes in accounting principles generally accepted in the United States (“GAAP”);~~

•~~lack of or insufficient amounts of insurance;~~

•~~the potential impact of severe weather events and climate change;~~

•~~other factors affecting the~~interpretations thereof, such as real estate ~~industry generally;~~and zoning laws and increases in real property tax rates, taxation of real estate investment trusts (“REITs”), and similar matters;

•our failure to maintain our qualification as a REIT for U.S. federal income tax purposes;

•limitations imposed on our business and our ability to satisfy complex rules in order for us to qualify as a REIT for U.S. federal income tax purposes;

•changes in accounting principles generally accepted in the United States (“GAAP”);

•lack of or insufficient amounts of insurance;

•other factors affecting the real estate industry generally; and

•other factors that may materially adversely affect us, or the per share trading price of our common shares, including:

•the number of our common shares available for future issuance or sale;

•our issuance of equity securities or the perception that such issuance might occur;

•future debt;

•failure of securities analysts to publish research or reports about us or our industry; and

•securities analysts’ downgrade of our common shares or the health care-related real estate sector.

While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events, or other changes after the date of this report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements. For a further discussion of these and other factors that could impact our future results, performance or transactions, see Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021~~2022 filed with the Securities and Exchange Commission (the “Commission”) on February 24, ~~2022~~2023 (the ~~“2021~~“2022 Annual Report”). and Part II, Item 1A of this report.

As used in this report, unless the context otherwise requires, references to “we,” “us,” “our,” and the “Company” refer to Physicians Realty Trust (the “Trust”), a Maryland real estate investment trust, and Physicians Realty L.P. (the “Operating Partnership”), a Delaware limited partnership and the consolidated subsidiary of the Trust through which we conduct our business.

Table of Contents

PART I. Financial Information

Item 1. Financial Statements

Physicians Realty Trust

Consolidated Balance Sheets

(In thousands, except share and per share data)


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
		(unaudited)					(unaudited)
ASSETS	ASSETS					ASSETS
Investment properties:	Investment properties:					Investment properties:
Land and improvements	Land and improvements	$	241,385	$	235,453	Land and improvements	$	249,468	$	241,559
Building and improvements	Building and improvements	4,666,085		4,612,561		Building and improvements	4,703,606		4,659,780
Construction in progress						Construction in progress	41,722		18,497
Tenant improvements	Tenant improvements	90,318		86,018		Tenant improvements	95,447		88,640
Acquired lease intangibles	Acquired lease intangibles	505,335		498,221		Acquired lease intangibles	509,468		505,335
		5,503,123		5,432,253			5,599,711		5,513,811
Accumulated depreciation	Accumulated depreciation	(948,883)		(821,036)		Accumulated depreciation	(1,140,208)		(996,888)
Net real estate property	Net real estate property	4,554,240		4,611,217		Net real estate property	4,459,503		4,516,923
Real estate held for sale		—		1,964

Right-of-use lease assets, net	Right-of-use lease assets, net	232,320		235,483		Right-of-use lease assets, net	227,967		231,225
Real estate loans receivable, net	Real estate loans receivable, net	120,576		117,844		Real estate loans receivable, net	79,883		104,973
Investments in unconsolidated entities	Investments in unconsolidated entities	79,613		69,793		Investments in unconsolidated entities	72,069		77,716
Net real estate investments	Net real estate investments	4,986,749		5,036,301		Net real estate investments	4,839,422		4,930,837
Cash and cash equivalents	Cash and cash equivalents	2,512		9,876		Cash and cash equivalents	195,772		7,730
Tenant receivables, net	Tenant receivables, net	9,644		4,948		Tenant receivables, net	11,131		11,503
Other assets	Other assets	143,569		131,584		Other assets	166,142		146,807
Total assets	Total assets	$	5,142,474	$	5,182,709	Total assets	$	5,212,467	$	5,096,877
LIABILITIES AND EQUITY	LIABILITIES AND EQUITY					LIABILITIES AND EQUITY
Liabilities:	Liabilities:					Liabilities:
Credit facility	Credit facility	$	256,893	$	267,641	Credit facility	$	393,090	$	188,328
Notes payable	Notes payable	1,465,078		1,464,008		Notes payable	1,451,536		1,465,437
Mortgage debt	Mortgage debt	164,556		180,269		Mortgage debt	127,630		164,352
Accounts payable	Accounts payable	6,526		6,651		Accounts payable	4,933		4,391
Dividends and distributions payable	Dividends and distributions payable	58,382		57,246		Dividends and distributions payable	60,928		60,148
Accrued expenses and other liabilities	Accrued expenses and other liabilities	92,494		86,254		Accrued expenses and other liabilities	95,637		87,720
Lease liabilities	Lease liabilities	104,905		104,957		Lease liabilities	104,802		105,011
Acquired lease intangibles, net	Acquired lease intangibles, net	24,970		21,569		Acquired lease intangibles, net	23,170		24,381
Total liabilities	Total liabilities	2,173,804		2,188,595		Total liabilities	2,261,726		2,099,768

Redeemable noncontrolling interests - partially owned properties	Redeemable noncontrolling interests - partially owned properties	3,288		7,081		Redeemable noncontrolling interests - partially owned properties	3,066		3,258

Equity:	Equity:					Equity:
Common shares, $0.01 par value, 500,000,000 common shares authorized, 226,763,146 and 224,678,116 common shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		2,268		2,247
Common shares, $0.01 par value, 500,000,000 common shares authorized, 238,482,769 and 233,292,030 common shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively						Common shares, $0.01 par value, 500,000,000 common shares authorized, 238,482,769 and 233,292,030 common shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	2,385		2,333
Additional paid-in capital	Additional paid-in capital	3,648,983		3,610,954		Additional paid-in capital	3,817,545		3,743,876
Accumulated deficit	Accumulated deficit	(838,729)		(776,001)		Accumulated deficit	(1,012,869)		(881,672)
Accumulated other comprehensive income (loss)		5,323		(892)
Accumulated other comprehensive income						Accumulated other comprehensive income	15,216		5,183
Total shareholders’ equity	Total shareholders’ equity	2,817,845		2,836,308		Total shareholders’ equity	2,822,277		2,869,720
Noncontrolling interests:	Noncontrolling interests:					Noncontrolling interests:
Operating Partnership	Operating Partnership	146,426		150,241		Operating Partnership	116,079		123,015
Partially owned properties	Partially owned properties	1,111		484		Partially owned properties	9,319		1,116
Total noncontrolling interests	Total noncontrolling interests	147,537		150,725		Total noncontrolling interests	125,398		124,131
Total equity	Total equity	2,965,382		2,987,033		Total equity	2,947,675		2,993,851
Total liabilities and equity	Total liabilities and equity	$	5,142,474	$	5,182,709	Total liabilities and equity	$	5,212,467	$	5,096,877

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Physicians Realty Trust

Consolidated Statements of Income

(In thousands, except share and per share data) (Unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Revenues:	Revenues:									Revenues:
Rental and related revenues	Rental and related revenues	$	127,381	$	110,314	$	381,785	$	326,017	Rental and related revenues	$	134,520	$	128,636	$	397,096	$	385,755
Interest income on real estate loans and other	Interest income on real estate loans and other	4,132		4,997		12,285		15,558		Interest income on real estate loans and other	4,027		2,877		10,895		8,315
Total revenues	Total revenues	131,513		115,311		394,070		341,575		Total revenues	138,547		131,513		407,991		394,070
Expenses:	Expenses:									Expenses:
Interest expense	Interest expense	18,299		13,498		52,356		40,754		Interest expense	20,050		18,299		59,837		52,356
General and administrative	General and administrative	10,079		9,534		30,400		28,116		General and administrative	9,771		10,079		31,133		30,400
Operating expenses	Operating expenses	43,647		35,679		128,080		103,069		Operating expenses	47,625		43,647		138,094		128,080
Depreciation and amortization	Depreciation and amortization	47,040		38,582		142,002		114,663		Depreciation and amortization	47,932		47,040		143,555		142,002
Impairment loss		—		340		—		340

Total expenses	Total expenses	119,065		97,633		352,838		286,942		Total expenses	125,378		119,065		372,619		352,838
Income before equity in loss of unconsolidated entities and gain on sale of investment properties, net:		12,448		17,678		41,232		54,633
Equity in loss of unconsolidated entities		(62)		(390)		(452)		(1,213)
Income before equity in (loss) gain of unconsolidated entities and gain on sale of investment properties, net:										Income before equity in (loss) gain of unconsolidated entities and gain on sale of investment properties, net:	13,169		12,448		35,372		41,232
Equity in (loss) gain of unconsolidated entities										Equity in (loss) gain of unconsolidated entities	(278)		(62)		1,260		(452)
Gain on sale of investment properties, net	Gain on sale of investment properties, net	53,894		4,757		57,375		5,111		Gain on sale of investment properties, net	—		53,894		13		57,375
Net income	Net income	66,280		22,045		98,155		58,531		Net income	12,891		66,280		36,645		98,155
Net income attributable to noncontrolling interests:	Net income attributable to noncontrolling interests:									Net income attributable to noncontrolling interests:
Operating Partnership	Operating Partnership	(3,252)		(529)		(4,830)		(1,405)		Operating Partnership	(505)		(3,252)		(1,443)		(4,830)
Partially owned properties (1)	Partially owned properties (1)	(70)		(152)		(384)		(455)		Partially owned properties (1)	(51)		(70)		(121)		(384)
Net income attributable to controlling interest		62,958		21,364		92,941		56,671
Preferred distributions		—		—		—		(13)

Net income attributable to common shareholders	Net income attributable to common shareholders	$	62,958	$	21,364	$	92,941	$	56,658	Net income attributable to common shareholders	$	12,335	$	62,958	$	35,081	$	92,941
Net income per share:	Net income per share:									Net income per share:
Basic	Basic	$	0.28	$	0.10	$	0.41	$	0.26	Basic	$	0.05	$	0.28	$	0.15	$	0.41
Diluted	Diluted	$	0.28	$	0.10	$	0.41	$	0.26	Diluted	$	0.05	$	0.28	$	0.15	$	0.41
Weighted average common shares:	Weighted average common shares:									Weighted average common shares:
Basic	Basic	226,529,041		217,406,657		225,743,856		214,616,482		Basic	238,480,299		226,529,041		238,124,981		225,743,856
Diluted	Diluted	239,898,462		223,992,049		239,145,383		221,399,649		Diluted	249,445,312		239,898,462		249,226,913		239,145,383

Dividends and distributions declared per common share	Dividends and distributions declared per common share	$	0.23	$	0.23	$	0.69	$	0.69	Dividends and distributions declared per common share	$	0.23	$	0.23	$	0.69	$	0.69

(1)Includes amounts attributable to redeemable noncontrolling interests.

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Physicians Realty Trust

Consolidated Statements of Comprehensive Income

(In thousands) (Unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Net income	Net income	$	66,280	$	22,045	$	98,155	$	58,531	Net income	$	12,891	$	66,280	$	36,645	$	98,155
Other comprehensive income:	Other comprehensive income:									Other comprehensive income:
Change in fair value of interest rate swap agreements, net	Change in fair value of interest rate swap agreements, net	1,753		465		6,215		1,805		Change in fair value of interest rate swap agreements, net	7,697		1,753		11,796		6,215
Reclassification of accumulated gains on interest rate swap to earnings										Reclassification of accumulated gains on interest rate swap to earnings	(1,763)		—		(1,763)		—
Total other comprehensive income	Total other comprehensive income	1,753		465		6,215		1,805		Total other comprehensive income	5,934		1,753		10,033		6,215
Comprehensive income	Comprehensive income	68,033		22,510		104,370		60,336		Comprehensive income	18,825		68,033		46,678		104,370
Comprehensive income attributable to noncontrolling interests - Operating Partnership	Comprehensive income attributable to noncontrolling interests - Operating Partnership	(3,336)		(541)		(5,137)		(1,449)		Comprehensive income attributable to noncontrolling interests - Operating Partnership	(739)		(3,336)		(1,839)		(5,137)
Comprehensive income attributable to noncontrolling interests - partially owned properties	Comprehensive income attributable to noncontrolling interests - partially owned properties	(70)		(152)		(384)		(455)		Comprehensive income attributable to noncontrolling interests - partially owned properties	(51)		(70)		(121)		(384)
Comprehensive income attributable to common shareholders	Comprehensive income attributable to common shareholders	$	64,627	$	21,817	$	98,849	$	58,432	Comprehensive income attributable to common shareholders	$	18,035	$	64,627	$	44,718	$	98,849

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Physicians Realty Trust

Consolidated Statements of Equity

(In thousands) (Unaudited)


		Par Value		Additional Paid in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity		Operating Partnership Noncontrolling Interest		Partially Owned Properties Noncontrolling Interest		Total Noncontrolling Interests		Total Equity			Par Value		Additional Paid in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity		Operating Partnership Noncontrolling Interest		Partially Owned Properties Noncontrolling Interest		Total Noncontrolling Interests		Total Equity
Balance at December 31, 2021		$	2,247	$	3,610,954	$	(776,001)	$	(892)	$	2,836,308	$	150,241	$	484	$	150,725	$	2,987,033
Balance at December 31, 2022																				Balance at December 31, 2022	$	2,333	$	3,743,876	$	(881,672)	$	5,183	$	2,869,720	$	123,015	$	1,116	$	124,131	$	2,993,851

Net proceeds from sale of common shares																				Net proceeds from sale of common shares	44		65,769		—		—		65,813		—		—		—		65,813
Restricted share award grants, net																				Restricted share award grants, net	5		(1,127)		(408)		—		(1,530)		—		—		—		(1,530)

Conversion of OP Units																				Conversion of OP Units	2		2,417		—		—		2,419		(2,419)		—		(2,419)		—
Dividends/distributions declared																				Dividends/distributions declared	—		—		(54,912)		—		(54,912)		(2,263)		—		(2,263)		(57,175)

Contributions																				Contributions	—		—		—		—		—		—		7,884		7,884		7,884
Distributions																				Distributions	—		—		—		—		—		—		(53)		(53)		(53)

Change in fair value of interest rate swap agreements																				Change in fair value of interest rate swap agreements	—		—		—		(1,021)		(1,021)		—		—		—		(1,021)
Adjustment for Noncontrolling Interests ownership in Operating Partnership																				Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(431)		—		—		(431)		431		—		431		—

Net income																				Net income	—		—		10,202		—		10,202		423		64		487		10,689
Balance as of March 31, 2023																				Balance as of March 31, 2023	$	2,384	$	3,810,504	$	(926,790)	$	4,162	$	2,890,260	$	119,187	$	9,011	$	128,198	$	3,018,458

Net proceeds from sale of common shares	Net proceeds from sale of common shares	3		5,029		—		—		5,032		—		—		—		5,032		Net proceeds from sale of common shares	—		294		—		—		294		—		—		—		294
Restricted share award grants, net	Restricted share award grants, net	3		118		(421)		—		(300)		—		—		—		(300)		Restricted share award grants, net	1		3,459		(561)		—		2,899		—		—		—		2,899
Purchase of OP Units	Purchase of OP Units	—		—		—		—		—		(184)		—		(184)		(184)		Purchase of OP Units	—		—		—		—		—		(72)		—		(72)		(72)

Dividends/distributions declared	Dividends/distributions declared	—		—		(51,879)		—		(51,879)		(2,740)		—		(2,740)		(54,619)		Dividends/distributions declared	—		—		(54,936)		—		(54,936)		(2,257)		—		(2,257)		(57,193)

Contributions	Contributions	—		—		—		—		—		—		569		569		569		Contributions	—		—		—		—		—		—		287		287		287
Distributions	Distributions	—		—		—		—		—		—		(55)		(55)		(55)		Distributions	—		—		—		—		—		—		(52)		(52)		(52)
Change in market value of Redeemable Noncontrolling Interest in partially owned properties		—		—		717		—		717		—		—		—		717

Change in fair value of interest rate swap agreement		—		—		—		1,379		1,379		—		—		—		1,379

Change in fair value of interest rate swap agreements																				Change in fair value of interest rate swap agreements	—		—		—		5,120		5,120		—		—		—		5,120
Adjustment for Noncontrolling Interests ownership in Operating Partnership	Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(217)		—		—		(217)		217		—		217		—		Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(393)		—		—		(393)		393		—		393		—

Net income	Net income	—		—		13,092		—		13,092		692		82		774		13,866		Net income	—		—		12,544		—		12,544		515		59		574		13,118
Balance as of March 31, 2022		$	2,253	$	3,615,884	$	(814,492)	$	487	$	2,804,132	$	148,226	$	1,080	$	149,306	$	2,953,438
Balance as of June 30, 2023																				Balance as of June 30, 2023	$	2,385	$	3,813,864	$	(969,743)	$	9,282	$	2,855,788	$	117,766	$	9,305	$	127,071	$	2,982,859

Net proceeds from sale of common shares		9		18,475		—		—		18,484		—		—		—		18,484

Restricted share award grants, net	Restricted share award grants, net	1		3,588		(911)		—		2,678		—		—		—		2,678		Restricted share award grants, net	—		3,746		(523)		—		3,223		—		—		—		3,223

Conversion of OP Units																				Conversion of OP Units	—		350		—		—		350		(350)		—		(350)		—
Dividends/distributions declared	Dividends/distributions declared	—		—		(52,116)		—		(52,116)		(2,712)		—		(2,712)		(54,828)		Dividends/distributions declared	—		—		(54,938)		—		(54,938)		(2,257)		—		(2,257)		(57,195)

Distributions	Distributions	—		—		—		—		—		—		(61)		(61)		(61)		Distributions	—		—		—		—		—		—		(53)		(53)		(53)
Change in market value of Redeemable Noncontrolling Interest in partially owned properties		—		—		527		—		527		—		—		—		527

Change in fair value of interest rate swap agreement		—		—		—		3,083		3,083		—		—		—		3,083
Reclassification of accumulated gains on interest rate swap to earnings																				Reclassification of accumulated gains on interest rate swap to earnings	—		—		—		(1,763)		(1,763)		—		—		—		(1,763)
Change in fair value of interest rate swap agreements																				Change in fair value of interest rate swap agreements	—		—		—		7,697		7,697		—		—		—		7,697
Adjustment for Noncontrolling Interests ownership in Operating Partnership	Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(488)		—		—		(488)		488		—		488		—		Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(415)		—		—		(415)		415		—		415		—

Net income	Net income	—		—		16,891		—		16,891		886		79		965		17,856		Net income	—		—		12,335		—		12,335		505		67		572		12,907
Balance as of June 30, 2022		$	2,263	$	3,637,459	$	(850,101)	$	3,570	$	2,793,191	$	146,888	$	1,098	$	147,986	$	2,941,177

Net proceeds from sale of common shares		5		7,925		—		—		7,930		—		—		—		7,930
Restricted share award grants, net		—		4,326		(536)		—		3,790		—		—		—		3,790
Purchase of OP Units		—		—		—		—		—		(2,139)		—		(2,139)		(2,139)

Dividends/distributions declared		—		—		(52,563)		—		(52,563)		(2,302)		—		(2,302)		(54,865)

Distributions		—		—		—		—		—		—		(61)		(61)		(61)
Change in market value of Redeemable Noncontrolling Interest in partially owned properties		—		—		1,513		—		1,513		—		—		—		1,513

Change in fair value of interest rate swap agreement		—		—		—		1,753		1,753		—		—		—		1,753
Adjustment for Noncontrolling Interests ownership in Operating Partnership		—		(727)		—		—		(727)		727		—		727		—

Net income		—		—		62,958		—		62,958		3,252		74		3,326		66,284
Balance as of September 30, 2022		$	2,268	$	3,648,983	$	(838,729)	$	5,323	$	2,817,845	$	146,426	$	1,111	$	147,537	$	2,965,382
Balance as of September 30, 2023																				Balance as of September 30, 2023	$	2,385	$	3,817,545	$	(1,012,869)	$	15,216	$	2,822,277	$	116,079	$	9,319	$	125,398	$	2,947,675

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Physicians Realty Trust

Consolidated Statements of Equity

(In thousands) (Unaudited)


		Par Value		Additional Paid in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity		Operating Partnership Noncontrolling Interest		Partially Owned Properties Noncontrolling Interest		Total Noncontrolling Interests		Total Equity			Par Value		Additional Paid in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity		Operating Partnership Noncontrolling Interest		Partially Owned Properties Noncontrolling Interest		Total Noncontrolling Interests		Total Equity
Balance at December 31, 2020		$	2,096	$	3,303,231	$	(658,171)	$	(5,859)	$	2,641,297	$	73,302	$	403	$	73,705	$	2,715,002
Balance at December 31, 2021																				Balance at December 31, 2021	$	2,247	$	3,610,954	$	(776,001)	$	(892)	$	2,836,308	$	150,241	$	484	$	150,725	$	2,987,033

Net proceeds from sale of common shares	Net proceeds from sale of common shares	28		52,404		—		—		52,432		—		—		—		52,432		Net proceeds from sale of common shares	3		5,029		—		—		5,032		—		—		—		5,032
Restricted share award grants, net	Restricted share award grants, net	4		(333)		(664)		—		(993)		—		—		—		(993)		Restricted share award grants, net	3		118		(421)		—		(300)		—		—		—		(300)
Purchase of OP Units	Purchase of OP Units	—		—		—		—		—		(269)		—		(269)		(269)		Purchase of OP Units	—		—		—		—		—		(184)		—		(184)		(184)

Dividends/distributions declared	Dividends/distributions declared	—		—		(49,011)		—		(49,011)		(1,243)		—		(1,243)		(50,254)		Dividends/distributions declared	—		—		(51,879)		—		(51,879)		(2,740)		—		(2,740)		(54,619)
Preferred distributions		—		—		(13)		—		(13)		—		—		—		(13)

Contributions																				Contributions	—		—		—		—		—		—		569		569		569
Distributions	Distributions	—		—		—		—		—		—		(73)		(73)		(73)		Distributions	—		—		—		—		—		—		(55)		(55)		(55)
Change in market value of Redeemable Noncontrolling Interests		—		(23)		896		—		873		—		—		—		873
Change in market value of Redeemable Noncontrolling Interest in partially owned properties																				Change in market value of Redeemable Noncontrolling Interest in partially owned properties	—		—		717		—		717		—		—		—		717

Change in fair value of interest rate swap agreements		—		—		—		797		797		—		—		—		797

Change in fair value of interest rate swap agreement																				Change in fair value of interest rate swap agreement	—		—		—		1,379		1,379		—		—		—		1,379
Adjustment for Noncontrolling Interests ownership in Operating Partnership	Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		1,136		—		—		1,136		(1,136)		—		(1,136)		—		Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(217)		—		—		(217)		217		—		217		—

Net income	Net income	—		—		17,194		—		17,194		459		76		535		17,729		Net income	—		—		13,092		—		13,092		692		82		774		13,866
Balance as of March 31, 2021		$	2,128	$	3,356,415	$	(689,769)	$	(5,062)	$	2,663,712	$	71,113	$	406	$	71,519	$	2,735,231
Balance as of March 31, 2022																				Balance as of March 31, 2022	$	2,253	$	3,615,884	$	(814,492)	$	487	$	2,804,132	$	148,226	$	1,080	$	149,306	$	2,953,438

Net proceeds from sale of common shares																				Net proceeds from sale of common shares	9		18,475		—		—		18,484		—		—		—		18,484
Restricted share award grants, net																				Restricted share award grants, net	1		3,588		(911)		—		2,678		—		—		—		2,678

Dividends/distributions declared																				Dividends/distributions declared	—		—		(52,116)		—		(52,116)		(2,712)		—		(2,712)		(54,828)

Distributions																				Distributions	—		—		—		—		—		—		(61)		(61)		(61)
Change in market value of Redeemable Noncontrolling Interest in partially owned properties																				Change in market value of Redeemable Noncontrolling Interest in partially owned properties	—		—		527		—		527		—		—		—		527

Change in fair value of interest rate swap agreement																				Change in fair value of interest rate swap agreement	—		—		—		3,083		3,083		—		—		—		3,083
Adjustment for Noncontrolling Interests ownership in Operating Partnership																				Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(488)		—		—		(488)		488		—		488		—

Net income																				Net income	—		—		16,891		—		16,891		886		79		965		17,856
Balance as of June 30, 2022																				Balance as of June 30, 2022	$	2,263	$	3,637,459	$	(850,101)	$	3,570	$	2,793,191	$	146,888	$	1,098	$	147,986	$	2,941,177

Net proceeds from sale of common shares	Net proceeds from sale of common shares	46		82,781		—		—		82,827		—		—		—		82,827		Net proceeds from sale of common shares	5		7,925		—		—		7,930		—		—		—		7,930
Restricted share award grants, net	Restricted share award grants, net	—		3,242		(482)		—		2,760		—		—		—		2,760		Restricted share award grants, net	—		4,326		(536)		—		3,790		—		—		—		3,790
Purchase of OP Units	Purchase of OP Units	—		—		—		—		—		(5,063)		—		(5,063)		(5,063)		Purchase of OP Units	—		—		—		—		—		(2,139)		—		(2,139)		(2,139)

Dividends/distributions declared	Dividends/distributions declared	—		—		(50,061)		—		(50,061)		(1,242)		—		(1,242)		(51,303)		Dividends/distributions declared	—		—		(52,563)		—		(52,563)		(2,302)		—		(2,302)		(54,865)

Distributions	Distributions	—		—		—		—		—		—		(50)		(50)		(50)		Distributions	—		—		—		—		—		—		(61)		(61)		(61)
Change in market value of Redeemable Noncontrolling Interests		—		—		(388)		—		(388)		—		—		—		(388)
Change in market value of Redeemable Noncontrolling Interest in partially owned properties																				Change in market value of Redeemable Noncontrolling Interest in partially owned properties	—		—		1,513		—		1,513		—		—		—		1,513

Change in fair value of interest rate swap agreements		—		—		—		543		543		—		—		—		543

Change in fair value of interest rate swap agreement																				Change in fair value of interest rate swap agreement	—		—		—		1,753		1,753		—		—		—		1,753
Adjustment for Noncontrolling Interests ownership in Operating Partnership	Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(2,124)		—		—		(2,124)		2,124		—		2,124		—		Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(727)		—		—		(727)		727		—		727		—

Net income	Net income	—		—		18,113		—		18,113		417		76		493		18,606		Net income	—		—		62,958		—		62,958		3,252		74		3,326		66,284
Balance as of June 30, 2021		$	2,174	$	3,440,314	$	(722,587)	$	(4,519)	$	2,715,382	$	67,349	$	432	$	67,781	$	2,783,163

Net proceeds from sale of common shares		—		(117)		—		—		(117)		—		—		—		(117)
Restricted share award grants, net		—		3,642		113		—		3,755		—		—		—		3,755

Dividends/distributions declared		—		—		(50,062)		—		(50,062)		(1,233)		—		(1,233)		(51,295)

Distributions		—		—		—		—		—		—		(51)		(51)		(51)
Change in market value of Redeemable Noncontrolling Interests		—		—		22		—		22		—		—		—		22

Change in fair value of interest rate swap agreements		—		—		—		465		465		—		—		—		465
Adjustment for Noncontrolling Interests ownership in Operating Partnership		—		(91)		—		—		(91)		91		—		91		—

Net income		—		—		21,364		—		21,364		529		76		605		21,969
Balance as of September 30, 2021		$	2,174	$	3,443,748	$	(751,150)	$	(4,054)	$	2,690,718	$	66,736	$	457	$	67,193	$	2,757,911
Balance as of September 30, 2022																				Balance as of September 30, 2022	$	2,268	$	3,648,983	$	(838,729)	$	5,323	$	2,817,845	$	146,426	$	1,111	$	147,537	$	2,965,382

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Physicians Realty Trust

Consolidated Statements of Cash Flows

(In thousands) (Unaudited)


		Nine Months Ended September 30,					Nine Months Ended September 30,
		2022		2021			2023		2022
Cash Flows from Operating Activities:	Cash Flows from Operating Activities:					Cash Flows from Operating Activities:
Net income	Net income	$	98,155	$	58,531	Net income	$	36,645	$	98,155
Adjustments to reconcile net income to net cash provided by operating activities	Adjustments to reconcile net income to net cash provided by operating activities					Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	Depreciation and amortization	142,002		114,663		Depreciation and amortization	143,555		142,002
Amortization of deferred financing costs	Amortization of deferred financing costs	1,739		1,744		Amortization of deferred financing costs	2,028		1,739
Amortization of lease inducements and above/below-market lease intangibles	Amortization of lease inducements and above/below-market lease intangibles	4,458		3,526		Amortization of lease inducements and above/below-market lease intangibles	4,055		4,458
Straight-line rental revenue/expense		(5,359)		(7,276)
Straight-line rental revenue, net						Straight-line rental revenue, net	(2,756)		(5,359)
Amortization of discount on unsecured senior notes	Amortization of discount on unsecured senior notes	794		489		Amortization of discount on unsecured senior notes	824		794
Amortization of above market assumed debt	Amortization of above market assumed debt	(10)		(47)		Amortization of above market assumed debt	—		(10)
Gain on extinguishment of debt						Gain on extinguishment of debt	(1,763)		—
Gain on sale of investment properties, net	Gain on sale of investment properties, net	(57,375)		(5,111)		Gain on sale of investment properties, net	(13)		(57,375)
Equity in loss of unconsolidated entities		452		1,213
Equity in (gain) loss of unconsolidated entities						Equity in (gain) loss of unconsolidated entities	(1,260)		452
Distributions from unconsolidated entities	Distributions from unconsolidated entities	6,077		5,261		Distributions from unconsolidated entities	5,707		6,077

Change in fair value of derivatives						Change in fair value of derivatives	185		—
Provision for bad debts	Provision for bad debts	269		(139)		Provision for bad debts	571		269
Non-cash share compensation	Non-cash share compensation	12,400		10,840		Non-cash share compensation	12,290		12,400

Impairment on investment property		—		340

Change in operating assets and liabilities:	Change in operating assets and liabilities:					Change in operating assets and liabilities:
Tenant receivables	Tenant receivables	(5,927)		(2,913)		Tenant receivables	711		(5,927)
Other assets	Other assets	(1,455)		3,300		Other assets	(3,019)		(1,455)
Accounts payable	Accounts payable	(125)		(1,247)		Accounts payable	542		(125)
Accrued expenses and other liabilities	Accrued expenses and other liabilities	6,258		(7,427)		Accrued expenses and other liabilities	7,610		6,258
Net cash provided by operating activities	Net cash provided by operating activities	202,353		175,747		Net cash provided by operating activities	205,912		202,353
Cash Flows from Investing Activities:	Cash Flows from Investing Activities:					Cash Flows from Investing Activities:
Proceeds from sale of investment properties	Proceeds from sale of investment properties	123,179		31,093		Proceeds from sale of investment properties	2,553		123,179
Acquisition of investment properties, net	Acquisition of investment properties, net	(111,587)		(120,617)		Acquisition of investment properties, net	(39,282)		(111,587)
Investment in unconsolidated entities		(13,349)		(7,281)
Investment in unconsolidated entities, net						Investment in unconsolidated entities, net	(3,671)		(13,349)
Returns of investment in unconsolidated entities						Returns of investment in unconsolidated entities	3,737		—
Development of real estate						Development of real estate	(12,672)		—
Escrowed cash - acquisition deposits/earnest deposits	Escrowed cash - acquisition deposits/earnest deposits	360		(1,154)		Escrowed cash - acquisition deposits/earnest deposits	—		360
Capital expenditures on investment properties	Capital expenditures on investment properties	(29,840)		(22,159)		Capital expenditures on investment properties	(31,194)		(29,840)
Investment in real estate loans receivable	Investment in real estate loans receivable	(29,618)		(14,406)		Investment in real estate loans receivable	(22,272)		(29,618)
Repayment of real estate loans receivable	Repayment of real estate loans receivable	22,441		18,902		Repayment of real estate loans receivable	41,065		22,441

Leasing commissions	Leasing commissions	(2,766)		(3,343)		Leasing commissions	(2,588)		(2,766)
Lease inducements	Lease inducements	(500)		—		Lease inducements	(399)		(500)
Net cash used in investing activities	Net cash used in investing activities	(41,680)		(118,965)		Net cash used in investing activities	(64,723)		(41,680)
Cash Flows from Financing Activities:	Cash Flows from Financing Activities:					Cash Flows from Financing Activities:
Net proceeds from sale of common shares	Net proceeds from sale of common shares	31,446		135,142		Net proceeds from sale of common shares	65,914		31,446
Proceeds from credit facility borrowings	Proceeds from credit facility borrowings	239,000		304,000		Proceeds from credit facility borrowings	513,000		239,000
Repayment of credit facility borrowings	Repayment of credit facility borrowings	(251,000)		(311,000)		Repayment of credit facility borrowings	(306,000)		(251,000)
Repayment of senior unsecured notes						Repayment of senior unsecured notes	(15,000)		—

Principal payments on mortgage debt	Principal payments on mortgage debt	(15,845)		(7,833)		Principal payments on mortgage debt	(36,803)		(15,845)
Debt issuance costs		(67)		(5,300)
Payments made on financing lease		—		(1,700)
Payment of debt issuance costs						Payment of debt issuance costs	(3,911)		(67)

Dividends paid - shareholders	Dividends paid - shareholders	(156,854)		(148,478)		Dividends paid - shareholders	(165,491)		(156,854)
Distributions to noncontrolling interests - Operating Partnership	Distributions to noncontrolling interests - Operating Partnership	(8,191)		(3,792)		Distributions to noncontrolling interests - Operating Partnership	(6,783)		(8,191)
Preferred distributions paid - OP Unit holder		—		(303)

Contributions from noncontrolling interest	Contributions from noncontrolling interest	569		—		Contributions from noncontrolling interest	8,171		569
Distributions to noncontrolling interests - partially owned properties	Distributions to noncontrolling interests - partially owned properties	(517)		(491)		Distributions to noncontrolling interests - partially owned properties	(281)		(517)
Payments of employee taxes for withheld stock-based compensation shares	Payments of employee taxes for withheld stock-based compensation shares	(4,255)		(4,183)		Payments of employee taxes for withheld stock-based compensation shares	(5,891)		(4,255)
Purchase of Series A Preferred Units		—		(4,661)

Purchase of OP Units	Purchase of OP Units	(2,323)		(5,332)		Purchase of OP Units	(72)		(2,323)
Net cash used in financing activities		(168,037)		(53,931)
Net (decrease) increase in cash and cash equivalents		(7,364)		2,851
Net cash provided by (used in) financing activities						Net cash provided by (used in) financing activities	46,853		(168,037)
Net increase (decrease) in cash and cash equivalents						Net increase (decrease) in cash and cash equivalents	188,042		(7,364)
Cash and cash equivalents, beginning of period	Cash and cash equivalents, beginning of period	9,876		2,515		Cash and cash equivalents, beginning of period	7,730		9,876
Cash and cash equivalents, end of period	Cash and cash equivalents, end of period	$	2,512	$	5,366	Cash and cash equivalents, end of period	$	195,772	$	2,512
Supplemental disclosure of cash flow information—interest paid during the period	Supplemental disclosure of cash flow information—interest paid during the period	$	57,977	$	49,160	Supplemental disclosure of cash flow information—interest paid during the period	$	66,082	$	57,977
Supplemental disclosure of noncash activity—settlement of note receivable in exchange for Series A Preferred Units		$	—	$	20,646

Supplemental disclosure of noncash activity—change in fair value of interest rate swap agreements	Supplemental disclosure of noncash activity—change in fair value of interest rate swap agreements	$	6,215	$	1,805	Supplemental disclosure of noncash activity—change in fair value of interest rate swap agreements	$	11,796	$	6,215
Supplemental disclosure of noncash activity—conversion of loan receivable in connection to the acquisition of investment property	Supplemental disclosure of noncash activity—conversion of loan receivable in connection to the acquisition of investment property	$	5,700	$	15,500	Supplemental disclosure of noncash activity—conversion of loan receivable in connection to the acquisition of investment property	$	5,398	$	5,700

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Physicians Realty Trust

Notes to Consolidated Financial Statements

Unless otherwise indicated or unless the context requires otherwise, the use of the words “we,” “us,” “our,” and the “Company,” refer to Physicians Realty Trust, together with its consolidated subsidiaries, including Physicians Realty L.P.

Note 1. Organization and Business

Physicians Realty Trust (the “Trust” or the “Company”) was organized in the state of Maryland on April 9, 2013. As of September 30, ~~2022,~~2023, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value $0.01 per share. The Trust filed a Registration Statement on Form S-11 with the Commission with respect to a proposed underwritten initial public offering (the “IPO”) and completed the IPO of its common shares and commenced operations on July 24, 2013.

The Trust contributed the net proceeds from the IPO to Physicians Realty L.P, a Delaware limited partnership (the “Operating Partnership”), and is the sole general partner of the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership.

The Trust is a self-managed REIT formed primarily to acquire, selectively develop, own, and manage health care properties that are leased to physicians, hospitals, and health care delivery systems.

ATM Program

In May 2021, the Trust and the Operating Partnership entered into an At Market Issuance Sales Agreement (the ~~“Sales~~“2021 Sales Agreement”) with KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., BMO Capital Markets Corp., and Raymond James & Associates, Inc. in their capacity as agents for the Company and/or forward sellers and Stifel, Nicolaus & Company, Incorporated in its capacity as sales agent for the Company (collectively, the ~~“Agents”~~“2021 Agents”) and Bank of Montreal, Credit Agricole Corporate and Investments Bank, KeyBanc Capital Markets Inc., and Raymond James & Associates, Inc. as forward purchasers for the Company (the ~~“Forward~~“2021 Forward Purchasers”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $500 million through the 2021 Agents (the ~~“ATM~~“2021 ATM Program”). The 2021 Sales Agreement contemplates that, in addition to the issuance and sale of the Trust’s common shares through the 2021 Agents, the Trust may also enter into one or more forward sales agreements from time to time in the future with each of the 2021 Forward Purchasers.

In August 2023, the Trust and the Operating Partnership entered into an At Market Issuance Sales Agreement (the “2023 Sales Agreement”) with BMO Capital Markets Corp., Credit Agricole Securities (USA) Inc., KeyBanc Capital Markets Inc., Raymond James & Associates, Inc., Regions Securities LLC and Stifel, Nicolaus & Company, Incorporated as sales agents for the Company and/or forward sellers (collectively, “2023 Agents”), and Bank of Montreal, Crédit Agricole Corporate and Investment Bank, KeyBanc Capital Markets Inc., Raymond James & Associates, Inc., Regions Securities LLC and Stifel, Nicolaus & Company, Incorporated (collectively, “2023 Forward Purchasers”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $600 million through the 2023 Agents (the “2023 ATM Program”). The 2023 Sales Agreement contemplates that, in addition to the issuance and sale of the Trust’s common shares through the 2023 Agents, the Trust may also enter into one or more forward sales agreements from time to time in the future with each of the 2023 Forward Purchasers. Upon entry into the 2023 Sales Agreement, we terminated the 2021 ATM Program.

During the quarters ended March 31, ~~2022,~~2023, June 30, ~~2022~~2023, and September 30, ~~2022,~~2023, the Trust issued and sold common shares through the 2021 ATM Program as follows (net proceeds in thousands):

Common
shares sold Weighted average price Net
proceeds
Quarter ended March 31, 2022 259,977 $ 18.93 $ 4,871
Quarter ended June 30, 2022 977,800 18.61 18,020
Quarter ended September 30, 2022 440,400 18.15 7,913
Year to date 1,678,177 $ 18.54 $ 30,804


	Common shares sold	Weighted average price		Net proceeds
Quarter ended March 31, 2023	4,400,000	$	15.10	$	65,776
Quarter ended June 30, 2023	—	—		—
Quarter ended September 30, 2023	—	—		—
Year to date	4,400,000	$	15.10	$	65,776

Table of Contents

As of September 30, ~~2022,~~2023, the Trust has ~~$300.1~~$600.0 million of common shares remaining available under the 2023 ATM Program. Subsequent to September 30, 2023, in connection with the Merger Agreement, the Trust suspended the 2023 ATM Program.

Note 2. Summary of Significant Accounting Policies

The accompanying unaudited consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the periods ended September 30, ~~2022~~2023 and ~~2021~~2022 pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements included in the Trust’s ~~2021~~2022 Annual Report. The Company has consistently applied its accounting policies to all periods presented in these consolidated financial statements.

~~Table of Contents~~

Noncontrolling Interests

The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets.

Operating Partnership: Noncontrolling interests in the Company include partnership interests of the Operating Partnership (“OP Units”) held by other investors. Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions.

As of September 30, ~~2022,~~2023, the Trust held a ~~95.1%~~96.1% interest in the Operating Partnership. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership.

Partially Owned Properties: The Trust reflects noncontrolling interests in partially owned properties on the consolidated balance sheets for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.

Redeemable Noncontrolling Interests - Partially Owned Properties

In connection with the Company’s acquisitions of the outpatient medical ~~office building,~~facility, ambulatory surgery center, and hospital located on the Great Falls Hospital campus in Great Falls, Montana, physicians affiliated with the sellers retained non-controlling interests which were, at the holders’ option, able to be redeemed at any time after May 1, 2023. Due to the redemption provision, which was outside of the control of the Trust, the Trust classified the investment in the mezzanine section of its consolidated balance sheets. On July 14, 2022, the Company disposed of these three properties and removed the related redeemable noncontrolling ~~interest~~interests from its consolidated balance sheets.

Through a consolidated joint venture with MedProperties Realty Advisors, LLC (“MedProperties”), the Company acquired Calko Medical Center in Brooklyn, New York. As part of the joint venture, MedProperties can redeem its interest, at ~~their~~its option, at any time after September 9, 2025. Due to the redemption provision, which is outside of the control of the Company, the Company classifies the noncontrolling interests in the mezzanine section of its consolidated balance sheets. The Company records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value.

Dividends and Distributions

On September ~~23, 2022,~~21, 2023, the Trust announced that its Board of Trustees authorized, and the Trust declared, a cash dividend of $0.23 per common share for the quarter ended September 30, ~~2022.~~2023. The dividend was paid on October ~~14, 2022~~17, 2023, to common shareholders and holders of record of ~~partnership interests of the Operating Partnership (“~~OP ~~Units”)~~Units as of the close of business on October ~~4, 2022.~~3, 2023.

Table of Contents

Tax Status of Dividends and Distributions

The Company’s distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain.

Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units).

The Company has elected taxable REIT subsidiary (“TRS”) status for certain of its corporate subsidiaries and, as a result, these entities will incur both federal and state income taxes on any taxable income of such entities after consideration of any net operating losses. To date, these income taxes have been de minimis.

~~Impairment of Intangible and Long-Lived Assets~~

The Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. The Company did not record impairment charges for the three and nine months ended September 30, 2022. The Company recorded an impairment charge of $0.3 million for the three and nine months ended September 30, 2021.

~~Table of Contents~~

~~Assets Held for Sale~~

The Company may sell properties from time to time for various reasons, including favorable market conditions. The Company classifies certain long-lived assets as held for sale once the criteria, as defined by GAAP, have been met. The Company classifies a real estate property as held for sale when: (i) management has approved the disposition of the property, (ii) the property is available for sale in its present condition, (iii) an active program to locate a buyer has been initiated, (iv) it is probable that the property will be disposed of within one year, (v) the property is being marketed at a reasonable price relative to its fair value, and (vi) it is unlikely that the disposition plan will significantly change or be withdrawn. Following the classification of a property as “held for sale,” no further depreciation or amortization is recorded for the asset and the book value of the asset is written down to the lower of carrying value or fair market value, less cost to sell. ~~As of September 30, 2022, the Company did not classify any properties as held for sale.~~

Real Estate Loans Receivable, Net

Real estate loans receivable consists of nine mezzanine loans, ~~five~~three term loans, and ~~one~~two construction ~~loan~~loans as of September 30, ~~2022.~~2023. Generally, each mezzanine loan is collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, each term loan is secured by a mortgage on a related outpatient medical ~~office building,~~facility, and construction loans are secured by mortgages on the land and the improvements as constructed. The reserve for loan losses was ~~$0.3~~$0.4 million as of September 30, ~~2022.~~2023.

Rental and Related Revenues

Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is probable. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due from tenants ~~excluding assets classified as held for sale,~~ are included in other assets and were approximately ~~$99.5~~$105.0 million and ~~$95.4~~$101.3 million as of September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively. If the Company determines that collectability of straight-line rents is not probable, income recognition is limited to the lesser of cash collected, or lease income reflected on a straight-line basis, plus variable rent when it becomes accruable.

In accordance with ASC 842, Leases, Topic 842, if the collectability of a lease changes after the commencement date, any difference between lease income that would have been recognized and the lease payments shall be recognized as an adjustment to lease income. Bad debt recognized as an adjustment to rental and related revenues was $0.9 million for the nine months ended September 30, 2023 and $0.2 million for the nine months ended September 30, ~~2022 and insignificant for the nine months ended September 30, 2021.~~2022.

Rental revenue is adjusted by the amortization of lease inducements and above-market or below-market rents on certain leases. Lease inducements and above-market or below-market rents are amortized on a straight-line basis over the remaining lease term. Rental and related revenues also include expense recoveries, which relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized in the period the applicable expenses are incurred. The reimbursements are recorded gross, as these costs are incurred by the Company and reimbursed by the tenants. ~~We have~~The Company has certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses and ~~we do~~the Company does not recognize expense recoveries.

Derivative Instruments

When the Company has derivative instruments, it records them either as an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sale exception. When specific hedge accounting criteria are not met or if the Company does not elect to apply for hedge accounting, changes in the Company’s derivative instruments’ fair value are recognized currently in earnings. If hedge accounting is applied to a derivative instrument, the entire change in the fair value of its derivatives designated and qualified as cash flow hedges are recorded in accumulated other comprehensive income (“AOCI”) on the consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings.

Table of Contents

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of September 30, 2023, the Company had three outstanding interest rate swaps designated as cash flow hedges of interest rate risk, and one interest rate swap that was de-designated as a hedging instrument during the quarter ended September 30, 2023 but remains outstanding. Further detail is provided in Note 7 (Derivatives).

Reclassifications

Certain amounts in the accompanying consolidated balance sheet for 2022 have been reclassified to conform to the 2023 consolidated financial statement presentation. The reclassifications had no impact on total assets or any balance sheet total or subtotal.

New Accounting Pronouncements

In March 2020, the ~~FASB~~Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting, ~~that~~which provides optional relief to applying reference rate reform to changing reference rates, contracts, hedging relationships, and other transactions that reference ~~LIBOR, which has been discontinued at~~ the ~~end of 2021.~~London Inter-Bank Offered Rate (“LIBOR”). The amendments in this update ~~are effective immediately and~~ may be applied through December 31, ~~2022, though in October 2022,~~2024.

On March 31, 2023, the ~~FASB extended this date through December 31, 2024.~~Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Third Amended and Restated Credit Agreement to update the benchmark provisions to replace LIBOR with the Secured Overnight Financing Rate (“SOFR”), as the reference rate for the purpose of calculating interest under the agreement. The Company ~~will continue~~also amended its fixed interest rate swap agreement on its mortgage debt to ~~use published~~update the reference rate from LIBOR ~~rates through June of 2023 at which time~~to SOFR. As a result, the Company ~~does~~elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients maintains the presentation of derivatives consistent with past presentation. The adoption of this ASU did not ~~expect the replacement benchmark to~~ have a material impact on the Company’s consolidated financial statements.

~~In August 2020, the FASB issued ASU 2020-06,~~ ~~Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)~~, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15,

~~Table of Contents~~

~~2021, with early adoption permitted. The Company adopted ASU 2020-06 on January 1, 2022, with no material effect on its consolidated financial statements.~~

Note 3. Investment and Disposition Activity

During the nine months ended September 30, ~~2022,~~2023, the Company executed contractual commitments related to a $40.5 million development project, with $12.7 million spent on construction in progress thus far, completed the acquisition of three outpatient medical facilities and three medical condominium units for an investment of $38.5 million and two parcels of land adjacent to existing outpatient medical ~~office~~ facilities for an investment of ~~$109.2~~$1.7 million, and ~~acquired~~paid $2.2 million of additional purchase consideration under six earn-out agreements. The Company also closed on a ~~49% membership interest~~$35.8 million construction loan, funding $10.7 million to date. Additionally, the Company funded an aggregate of $13.2 million on new term loans, previously announced loan commitments, and other investments, including an $1.3 million investment in ~~three properties through~~IJRI Properties, LLC, which is an entity constructing and operating an outpatient medical facility in Indiana. The Company contributed $2.0 million to the joint venture with Davis Medical Investors, LLC (the “Davis Joint Venture”) ~~for an aggregate purchase price of $8.0 million. The Company also paid $6.0 million of~~to fund additional purchase consideration ~~under three earn-out agreements and funded one mezzanine loan for $5.8~~related to the venture’s acquisitions. Investment activity totaled approximately $81.0 million ~~three term loans for $22.2 million, and $1.7 million of previous construction loan commitments. Additionally,~~during the ~~Company invested $4.7 million in funds managed by a real estate technology private equity fund, resulting in total investment activity of approximately $157.6 million as of~~nine months ended September 30, ~~2022.~~2023. As part of these investments, the Company incurred approximately ~~$2.2~~$2.0 million of capitalized acquisition costs.

Investment activity for the three months ended September 30, ~~2022,~~2023, included the acquisition of one outpatient medical ~~office~~ facility and a parcel of land adjacent to one of our existing properties for aan aggregate purchase price of ~~$81.5~~$3.5 million. Additionally, the Company funded an aggregate $5.9 million and the funding of two term loans for $14.1 million, $0.6 million of a previously announced term loan, and $0.4 million of previous construction loan commitments. The Company also paid $5.0 million of additional purchase consideration under two earn-out agreements, previously announced loan commitments, and ~~invested $0.3~~other investments, including an $1.3 million investment in ~~funds managed by a real estate technology private equity fund,~~IJRI Properties, LLC, which is an entity constructing and operating an outpatient medical facility in Indiana. The Company also funded construction in progress of $7.4 million, resulting in total investment activity of approximately ~~$101.7~~$16.8 million as of September 30, ~~2022.~~2023.

Table of Contents

The following table summarizes the acquisition date fair values of the assets acquired and the liabilities assumed, ~~in connection with the acquisition of the two medical office facilities,~~ as well as follow-on capitalized costs during the nine months ended September 30, ~~2022,~~2023, which the Company determined using Level 2 and Level 3 inputs (in thousands):


		1st Quarter		2nd Quarter		3rd Quarter		Total			1st Quarter		2nd Quarter		3rd Quarter		Total
Land	Land	$	—	$	1,400	$	7,685	$	9,085	Land	$	1,356	$	6,016	$	1,345	$	8,717
Building and improvements	Building and improvements	—		25,119		72,621		97,740		Building and improvements	1,294		28,353		2,459		32,106
In-place lease intangibles	In-place lease intangibles	—		2,839		10,006		12,845		In-place lease intangibles	—		3,491		919		4,410
Above market in-place lease intangibles		—		588		2,180		2,768

Below market in-place lease intangibles	Below market in-place lease intangibles	—		—		(4,923)		(4,923)		Below market in-place lease intangibles	—		—		(553)		(553)
Right-of-use asset		—		79		—		79

Net assets acquired	Net assets acquired	$	—	$	30,025	$	87,569	$	117,594	Net assets acquired	$	2,650	$	37,860	$	4,170	$	44,680

Satisfaction of real estate loans receivable	Satisfaction of real estate loans receivable	—		(2,700)		—		(2,700)		Satisfaction of real estate loans receivable	—		(5,398)		—		(5,398)
NCI-redeemable		—		—		(3,307)		(3,307)

Cash used in acquisition of investment property	Cash used in acquisition of investment property	$	—	$	27,325	$	84,262	$	111,587	Cash used in acquisition of investment property	$	2,650	$	32,462	$	4,170	$	39,282

Dispositions

During the nine months ended September 30, ~~2022,~~2023, the Company sold ~~five~~one outpatient medical ~~facilities, which included four medical office buildings and one hospital, representing 212,295 square feet~~facility for approximately ~~$124.7~~$2.6 million, realizing an ~~aggregate net gain of approximately $57.4 million.~~insignificant gain.

~~Table of Contents~~

Note 4. Intangibles

The following is a summary of the carrying amount of intangible assets and liabilities ~~excluding assets classified as held for sale if applicable,~~ as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 (in thousands):


		September 30, 2022						December 31, 2021							September 30, 2023						December 31, 2022
		Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net			Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
Assets	Assets													Assets
In-place leases	In-place leases	$	445,583	$	(230,930)	$	214,653	$	441,072	$	(201,885)	$	239,187	In-place leases	$	449,716	$	(272,643)	$	177,073	$	445,583	$	(241,643)	$	203,940
Above-market leases	Above-market leases	$	59,752	$	(28,662)	$	31,090	$	57,149	$	(24,437)	$	32,712	Above-market leases	$	59,752	$	(34,282)	$	25,470	$	59,752	$	(30,096)	$	29,656
Liabilities	Liabilities													Liabilities
Below-market leases	Below-market leases	$	37,002	$	(12,032)	$	24,970	$	32,155	$	(10,585)	$	21,570	Below-market leases	$	36,962	$	(13,792)	$	23,170	$	37,002	$	(12,621)	$	24,381

The following is a summary of acquired lease intangible amortization for the three and nine ~~month periods~~months ended September 30, ~~2022~~2023 and ~~2021~~2022 (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Amortization expense related to in-place leases	Amortization expense related to in-place leases	$	10,629	$	8,103	$	32,814	$	24,590	Amortization expense related to in-place leases	$	10,204	$	10,629	$	31,278	$	32,814
Decrease in rental income related to above-market leases	Decrease in rental income related to above-market leases	1,384		897		4,390		2,744		Decrease in rental income related to above-market leases	1,373		1,384		4,187		4,390
Increase in rental income related to below-market leases	Increase in rental income related to below-market leases	556		324		1,522		963		Increase in rental income related to below-market leases	594		556		1,764		1,522

Future aggregate net amortization of acquired lease intangibles as of September 30, ~~2022,~~2023, is as follows (in thousands):


		Net Decrease in Revenue		Net Increase in Expenses			Net Decrease (Increase) in Revenue		Net Increase in Expenses
2022		$	845	$	10,712
2023	2023	3,191		40,616		2023	$	748	$	9,642
2024	2024	2,929		34,718		2024	2,887		35,184
2025	2025	2,357		29,208		2025	2,316		29,663
2026	2026	1,203		23,095		2026	1,161		23,548
2027						2027	994		20,625
Thereafter	Thereafter	(4,405)		76,304		Thereafter	(5,806)		58,411
Total	Total	$	6,120	$	214,653	Total	$	2,300	$	177,073

Table of Contents

As of September 30, ~~2022,~~2023, the weighted average remaining amortization period is 7 years for in-place and above-market lease ~~intangibles~~intangible assets and 1615 years for below-market lease intangibles.

~~Table of Contents~~

Note 5. Other Assets

Other assets consisted of the following ~~excluding assets classified as held for sale, if applicable,~~ as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 (in thousands):


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Straight line rent receivable, net	Straight line rent receivable, net	$	99,494	$	95,443	Straight line rent receivable, net	$	104,991	$	101,306
Interest rate swaps						Interest rate swaps	14,731		2,045
Leasing commissions, net						Leasing commissions, net	14,043		13,231
Prepaid expenses	Prepaid expenses	13,866		8,910		Prepaid expenses	14,013		11,009
Leasing commissions, net		12,887		11,627
Lease inducements, net	Lease inducements, net	8,119		8,293		Lease inducements, net	7,577		7,894
Interest rate swap		2,071		—
Escrows	Escrows	1,434		1,780		Escrows	1,574		1,565
Notes receivable, net	Notes receivable, net	1,326		1,097		Notes receivable, net	363		370
Other	Other	4,372		4,434		Other	8,850		9,387
Total	Total	$	143,569	$	131,584	Total	$	166,142	$	146,807

Note 6. Debt

The following is a summary of debt as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 (in thousands):


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Fixed interest mortgage notes (1)	Fixed interest mortgage notes (1)	$	59,906	$	75,395	Fixed interest mortgage notes (1)	$	23,330	$	59,776
Variable interest mortgage notes (2)	Variable interest mortgage notes (2)	105,272		105,629		Variable interest mortgage notes (2)	104,797		105,153
Total mortgage debt	Total mortgage debt	165,178		181,024		Total mortgage debt	128,127		164,929
$1.0 billion unsecured revolving credit facility bearing variable interest of LIBOR plus 0.85%, due September 2025		262,000		274,000
$1.0 billion unsecured revolving credit facility due September 2025 (3)						$1.0 billion unsecured revolving credit facility due September 2025 (3)	—		193,000
$400 million unsecured term borrowing bearing fixed interest of 4.693%, due May 2028 (4)						$400 million unsecured term borrowing bearing fixed interest of 4.693%, due May 2028 (4)	400,000		—
$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027	$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027	400,000		400,000		$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027	400,000		400,000
$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028	$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028	350,000		350,000		$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028	350,000		350,000
$500 million senior unsecured notes bearing fixed interest of 2.625%, due November 2031	$500 million senior unsecured notes bearing fixed interest of 2.625%, due November 2031	500,000		500,000		$500 million senior unsecured notes bearing fixed interest of 2.625%, due November 2031	500,000		500,000
$150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031		150,000		150,000
$135 million senior unsecured notes bearing fixed interest of 4.43% to 4.74%, due January 2026 to 2031						$135 million senior unsecured notes bearing fixed interest of 4.43% to 4.74%, due January 2026 to 2031	135,000		150,000
$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027	$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027	75,000		75,000		$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027	75,000		75,000
Total principal	Total principal	1,902,178		1,930,024		Total principal	1,988,127		1,832,929
Unamortized deferred financing costs	Unamortized deferred financing costs	(8,022)		(9,694)		Unamortized deferred financing costs	(9,336)		(7,453)
Unamortized discounts	Unamortized discounts	(7,629)		(8,423)		Unamortized discounts	(6,535)		(7,359)
Unamortized fair value adjustments		—		11

Total debt	Total debt	$	1,886,527	$	1,911,918	Total debt	$	1,972,256	$	1,818,117

(1)As of September 30, 2023, one fixed interest mortgage note bears interest of 4.63%, due in 2024, and is collateralized by one property with a net book value of $37.2 million. As of December 31, 2022, fixed interest mortgage notes bear interest from 3.33% to 4.63%, due in 2024, with a weighted average interest rate of 3.85%. ~~As of December 31, 2021, fixed interest mortgage notes bear interest from 3.33% to 4.83%, due in 2022 and 2024, with a weighted average interest rate of 4.05%.~~ The notes are collateralized by two properties with a net book value of ~~$95.7 million as of September 30, 2022 and three properties with a net book value of $151.9 million as of December 31, 2021. One~~$94.9 million. one mortgage note bears interest at LIBOR +plus 1.90% and the Trust entered into a pay-fixed receive-variable interest rate swap, fixing the ~~LIBOR~~variable component ~~of this rate~~ at 1.43%. as of December 31, 2022.

(2)Variable interest mortgage notes bear variable interest of ~~LIBOR +~~SOFR plus 1.85% and PRIME plus 2.75% ~~and SOFR + 1.85%~~ for a weighted average interest rate of ~~4.87% and 1.95%~~7.35% as of September 30, ~~2022~~2023. Variable interest mortgage notes bear variable interest of SOFR plus 1.85% and LIBOR plus 2.75% for a weighted average interest rate of 6.20% as of December 31, ~~2021, respectively.~~2022. The notes are due in 2026 and 2028 and collateralized by four properties with a net book value of ~~$297.7~~$284.4 million as of September 30, ~~2022~~2023 and ~~$307.2~~$295.5 million as of December 31, ~~2021.~~2022.

(3)The unsecured revolving credit facility bears variable interest of SOFR plus 0.95%, inclusive of a 0.10% SOFR index adjustment, as of September 30, 2023 and LIBOR plus 0.85% as of December 31, 2022.

Table of Contents

(4)The Company’s borrowings under the term loan feature of the Credit Agreement (as defined below) bear interest at a rate equal to 1.10%, inclusive of a 0.10% SOFR index adjustment, plus Daily Simple SOFR as of September 30, 2023 based on the Company’s current credit rating. The Company entered into fixed-for-floating interest rate swaps for the full borrowing amount, fixing the SOFR component of this rate at 3.59%, and a current all-in fixed rate of 4.69%.

On September 24, 2021, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a Third Amended and Restated Credit Agreement ~~(the~~(as amended, the “Credit Agreement”) which extended the maturity date of the revolving credit facility under the Credit Agreement to September 24, 2025 and reduced the interest rate margin applicable to borrowings. The

~~Table of Contents~~

Credit Agreement ~~includes~~included an unsecured revolving credit facility of $1.0 billion and ~~contains~~contained a term loan feature of $250.0 million, bringing total borrowing capacity to ~~$1.3~~$1.25 billion. The Credit Agreement also ~~includes~~included a swingline loan commitment for up to 10% of the maximum principal amount and ~~provides~~provided an accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.75 billion. The revolving credit facility under the Credit Agreement also ~~includes~~included two six-month extension options.

On March 31, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Credit Agreement which expanded the accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, and replaced the LIBOR-based benchmark rates applicable to borrowings under the Credit Agreement with SOFR based benchmark rates plus a SOFR index adjustment of 0.10%.

On May 24, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a Second Amendment to the Credit Agreement, which added a new $400.0 million unsecured term loan with a scheduled maturity date of May 24, 2028 and expanded the accordion feature, which allows the Operating Partnership to increase borrowing capacity under the Credit Agreement by up to an additional $500.0 million, subject to customary terms and conditions, for a maximum aggregate principal amount of all revolving commitments and term loans under the Credit Agreement of $1.9 billion. On the same day, the Operating Partnership borrowed $400.0 million under the term loan feature of the Credit Agreement. Borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at ~~an adjusted LIBOR~~a rate ~~which is based on the Trust’s investment grade rating under~~equal to 1.10%, inclusive of a 0.10% SOFR index adjustment, plus Daily Simple SOFR as defined in the Credit Agreement. The Company simultaneously entered into fixed-for-floating interest rate swaps for the full borrowing amount under the term loan, fixing the Daily Simple SOFR component of the borrowing rate at 3.593%, for a current all-in fixed rate of 4.693%. Both the borrowing and the fixed-for-floating interest rate swaps have a maturity date of May 24, 2028.

As of September 30, ~~2022,~~2023, the ~~Trust~~borrower had investment grade ratings of BBB from S&P and Baa2 from Moody’s. As such, borrowings under the revolving credit facility of the Credit Agreement accrue interest on the outstanding principal at a rate of ~~LIBOR + 0.85%.~~SOFR plus 0.95%, inclusive of a 0.10% SOFR index adjustment. The Credit Agreement includes a facility fee equal to 0.20% per annum, which is also determined by the ~~Trust’s~~borrower’s investment grade rating.

On October 13, 2021, the Operating Partnership issued $500.0 million in aggregate principal amount of 2.625% Senior Notes due November 1, 2031 (the “2031 Senior Notes”) in a public offering and the Company used the proceeds from the 2031 Senior Notes to pay off a $250.0 million term loan feature of the Credit Agreement. The Operating Partnership simultaneously terminated the existing pay-fixed receive-variable rate swaps associated with the full term loan borrowing of $250.0 million. As part of the termination, the Company made total cash payments of $3.3 million to the counterparties of the swap agreements. As defined by the Credit Agreement, the term loan feature is no longer available to the Company.

Base Rate Loans, Adjusted ~~LIBOR Rate~~SOFR Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the ~~Trust’s~~borrower’s investment grade rating as follows:


Credit Rating	Credit Rating	Applicable Margin for Revolving Loans: LIBOR Rate Loans and Letter of Credit Fee	Applicable Margin for Revolving Loans: Base Rate Loans		Applicable Margin for Term Loans: LIBOR Rate Loans and Letter of Credit Fee	Applicable Margin for Term Loans: Base Rate Loans		Credit Rating	Applicable Margin for Revolving Loans: SOFR Loans and Letter of Credit Fee	Applicable Margin for Revolving Loans: Base Rate Loans		Applicable Margin for Term Loans: SOFR Loans	Applicable Margin for Term Loans: Base Rate Loans
At Least A- or A3	At Least A- or A3	LIBOR + 0.725%	—	%	LIBOR + 0.85%	—	%	At Least A- or A3	SOFR + 0.725%	—	%	SOFR + 0.85%	—	%
At Least BBB+ or Baa1	At Least BBB+ or Baa1	LIBOR + 0.775%	—	%	LIBOR + 0.90%	—	%	At Least BBB+ or Baa1	SOFR + 0.775%	—	%	SOFR + 0.90%	—	%
At Least BBB or Baa2	At Least BBB or Baa2	LIBOR + 0.85%	—	%	LIBOR + 1.00%	—	%	At Least BBB or Baa2	SOFR + 0.85%	—	%	SOFR + 1.00%	—	%
At Least BBB- or Baa3	At Least BBB- or Baa3	LIBOR + 1.05%	0.05	%	LIBOR + 1.25%	0.25	%	At Least BBB- or Baa3	SOFR + 1.05%	0.05	%	SOFR + 1.25%	0.25	%
Below BBB- or Baa3	Below BBB- or Baa3	LIBOR + 1.40%	0.40	%	LIBOR + 1.65%	0.65	%	Below BBB- or Baa3	SOFR + 1.40%	0.40	%	SOFR + 1.65%	0.65	%

The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust’s and the Operating Partnership’s ability to incur additional debt, grant liens, or make distributions. ~~The~~Subject to the restrictions in the Merger Agreement, the Company may ~~at any time,~~ voluntarily prepay any revolving or term loan under the Credit Agreement in whole or in part without premium or penalty. As of September 30, ~~2022,~~2023, the Company was in compliance with all financial covenants related to the Credit Agreement.

Table of Contents

The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.

As of September 30, ~~2022,~~2023, the Company did not have any borrowings outstanding under its $1.0 billion unsecured revolving credit facility feature or the $500.0 million accordion feature of the Credit Agreement and had ~~$262.0~~$400.0 million of borrowings outstanding under ~~its unsecured revolving credit facility. As defined by~~the term loan feature of the Credit ~~Agreement, the current unencumbered borrowing base allows the Company to borrow an additional $738.0 million before reaching the maximum allowed under the credit facility.~~Agreement.

Notes Payable

As of September 30, ~~2022,~~2023, the Company had $1.5 billion aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, comprised of ~~$15.0 million maturing in 2023,~~ $25.0 million maturing in 2025, $70.0 million maturing in 2026, $425.0 million maturing in 2027, $395.0 million maturing in 2028, and $545.0 million maturing in 2031.

Certain properties ~~have~~are encumbered by mortgage ~~debt~~loans that ~~contains~~contain financial covenants. As of September 30, ~~2022,~~2023, the Trust was in compliance with all mortgage debt financial covenants.

~~Table of Contents~~

Scheduled principal payments due on consolidated debt as of September 30, ~~2022~~2023 are as follows (in thousands):


2022		$	248
2023	2023	16,008		2023	$	255
2024	2024	59,719		2024	23,669
2025	2025	287,476		2025	25,476
2026	2026	170,476		2026	170,476
2027				2027	425,476
Thereafter	Thereafter	1,368,251		Thereafter	1,342,775
Total Payments	Total Payments	$	1,902,178	Total Payments	$	1,988,127

As of September 30, ~~2022,~~2023, the Company had total consolidated indebtedness of approximately ~~$1.9~~$2.0 billion. The weighted average interest rate on consolidated indebtedness was ~~3.75%~~4.07% (based on the 30-day ~~LIBOR rate of 2.92% and a~~ SOFR rate of ~~2.98%~~5.31% and a PRIME rate of 8.50% as of September 30, ~~2022)~~2023). As of September 30, 2023, we had approximately 5.0% and 0.2% of our outstanding long-term debt exposed to fluctuations in SOFR and PRIME, respectively.

For the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, the Company incurred interest expense on its debt, exclusive of deferred financing cost amortization, of ~~$17.7~~$21.0 million and ~~$12.9~~$17.7 million, respectively. For the nine ~~months ended~~month periods ending September 30, ~~2022~~2023 and ~~2021,~~2022, the Company incurred interest expense on its debt, exclusive of deferred financing cost amortization, of ~~$50.6~~$59.6 million and ~~$39.0~~$50.6 million, respectively.

Note 7. Derivatives

In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. ~~The Company has implemented ASC 815,~~ ~~Derivatives and Hedging~~ (“ASC 815”), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception.

When specific hedge accounting criteria are not met, ~~ASC 815 requires~~ that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. As a result of the Company’s adoption of ASU 2017-12 as of January 1, 2019, the ~~entire~~ change in the fair value of ~~its~~our derivatives designated and qualified as cash flow hedges are recorded in accumulated other comprehensive income on the consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings. During the three months ended September 30, 2023, the Company de-designated an interest rate swap upon the repayment of the related debt instrument and reclassified the $1.8 million accumulated gain from other comprehensive income to earnings. This derivative instrument has a fair value of $1.6 million as of September 30, 2023, and is classified in other assets. Future changes in value on this derivative instrument, which matures on October 31, 2024, will be recorded directly in earnings.

~~To manage interest rate risk for certain~~As of ~~its variable-rate debt,~~September 30, 2023, the Company ~~uses~~had three outstanding interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of September 30, 2022, the Company had one outstanding interest rate swap contract designated as a cash flow hedge of interest rate risk. See Note 2 (Summary of Significant Accounting Policies) ~~of the 2021 Annual Report~~ for a further discussion of our derivatives. In

Table of Contents

addition, the Company recognizes its share of other comprehensive income ~~(loss)~~ related to derivative instruments held by unconsolidated entities.

The following table ~~summarizes~~presents the ~~location and aggregate~~ fair value of the Company’s derivative financial instruments, as well as their classification on the Company’s consolidated balance sheets as of September 30, 2023 (in thousands):


Derivatives Instruments	Maturity Date	Number of Instruments	Total Notional Amount		Interest Rate		Balance Sheet Location	Fair Value
Cash flow hedge interest rate swaps	5/24/2028	3	$	400,000	3.59	%	Other Assets	$	13,152
Interest rate swap	10/31/2024	1	36,050		1.37	%	Other Assets	1,579
Total		4	$	436,050				$	14,731

The following tables provide a summary of the effect of interest rate swaps on the Company’s accompanying consolidated ~~balance sheets (in~~statements of income and comprehensive income for the nine months ended September 30, 2023 and 2022, respectively (amounts in thousands):

Total notional amount $ 36,050
Effective fixed interest rate (1) 3.33 %
Effective date 10/31/2019
Maturity date 10/31/2024
Asset balance at September 30, 2022 (included in Other assets) $ 2,071
Liability balance at December 31, 2021 (included in Accrued expenses and other liabilities) $ 452

~~(1)1.43% effective swap rate plus 1.90% spread per hedging agreement.~~


Derivative Instruments as of September 30, 2023	Maturity Date	Amount of Gain/(Loss) Recognized in OCI on Derivative		Location of Gain/(Loss) Reclassified from Accumulated OCI into Income	Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income
Cash flow hedge interest rate swaps	5/24/2028	$	13,152	Interest expense	$	—
Interest rate swap	10/31/2024	—		Interest expense	1,763
Total		$	13,152		$	1,763

Derivative Instruments as of

September 30, 2022

Maturity Date

Amount of Gain/(Loss) Recognized in OCI on Derivative

Location of Gain/(Loss) Reclassified from Accumulated OCI into Income

Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income

Interest rate swap

10/31/2024

2,523

Interest expense

—

~~Table of Contents~~

Note 8. Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consisted of the following as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 (in thousands):


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Real estate taxes payable	Real estate taxes payable	$	29,173	$	23,487	Real estate taxes payable	$	30,893	$	23,303
Prepaid rent	Prepaid rent	24,556		22,714		Prepaid rent	23,537		21,062
Accrued interest	Accrued interest	11,208		18,799		Accrued interest	11,683		18,196
Accrued expenses	Accrued expenses	8,694		5,960		Accrued expenses	7,841		7,920
Accrued incentive compensation	Accrued incentive compensation	5,166		1,784		Accrued incentive compensation	5,342		2,700
Security deposits	Security deposits	4,451		4,234		Security deposits	4,586		4,338
Tenant improvement allowances	Tenant improvement allowances	1,831		1,857		Tenant improvement allowances	1,853		1,831
Interest rate swap		—		452

Other	Other	7,415		6,967		Other	9,902		8,370
Total	Total	$	92,494	$	86,254	Total	$	95,637	$	87,720

Table of Contents

Note 9. Stock-based Compensation

The Company follows ASC 718, Compensation - Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances.

Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available.

In connection with the IPO, the Trust adopted the Physicians Realty Trust 2013 Equity Incentive Plan, which made shares available for awards for ~~participants. On April 30, 2019, at~~participants (the “2013 Plan”). At the Company’s Annual Meeting of Shareholders ~~of Physicians Realty Trust, the Trust’s~~held on May 3, 2023, shareholders approved the Amended and Restated Physicians Realty Trust 2013 Equity Incentive Plan (“(the “Amended and Restated 2013 Plan”). The ~~amendment~~Amended and Restated 2013 Plan increased the number of common shares authorized for issuance ~~under the 2013 Plan~~ to a total of ~~7,000,000 common shares authorized for issuance.~~11,000,000. The Amended and Restated 2013 Plan ~~term was~~ also extended the term of the plan from 2029 to ~~2029.~~2033, among other changes.

Restricted Common Shares

Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. In the nine ~~month period~~months ended September 30, ~~2022,~~2023, the Trust granted a total of ~~247,579~~342,939 restricted common shares with a total value of ~~$4.1~~$5.0 million to its officers and certain of its ~~employees. These awards~~employees, which have a vesting period of one to three years. In January 2023, under the 2013 Plan, the Company granted restricted common shares to certain of its officers under a salary deferral program, part of which vests after one year, with the remainder vesting after two years.

~~Table of Contents~~

A summary of the status of the Trust’s non-vested restricted common shares as of September 30, ~~2022~~2023 and changes during the nine month period then ended follow:


		Common Shares	Weighted Average Grant Date Fair Value			Common Shares	Weighted Average Grant Date Fair Value
Non-vested at December 31, 2021		247,447	$	17.41
Non-vested at December 31, 2022					Non-vested at December 31, 2022	272,898	$	16.69
Granted	Granted	247,579	16.53		Granted	342,939	14.57
Vested	Vested	(213,572)	17.29		Vested	(239,602)	16.54
Forfeited	Forfeited	(5,356)	18.01		Forfeited	(364)	17.45
Non-vested at September 30, 2022		276,098	$	16.70
Non-vested at September 30, 2023					Non-vested at September 30, 2023	375,871	$	14.84

For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, the Company recognized non-cash share compensation of $1.2 million and $1.0 ~~million.~~million, respectively. For the nine ~~months ended~~month periods ending September 30, ~~2022~~2023 and ~~2021,~~2022, the Company recognized non-cash share compensation of ~~$2.9~~$3.5 million and ~~$2.8~~$2.9 million, respectively. Unrecognized compensation expense aton September 30, ~~2022~~2023 was ~~$2.5~~$2.9 million.

Table of Contents

Restricted Share Units

In January ~~2022,~~2023, under the 2013 Plan, the Company granted ~~7,800~~11,274 restricted share units to certain of its trustees in lieu of all or a portion of such trustee’s ~~2022~~2023 cash retainer. These units are subject to certain timing conditions and a one-year service period. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend. With respect to the performance and timing conditions of the January ~~2022~~2023 grants, the grant date fair value of ~~$18.83~~$14.47 per unit was based on the share price at the date of grant.

In March ~~2022,~~2023, under the 2013 Plan, the Company granted restricted share units at a target level of ~~299,019~~355,388 to its officers and certain of its employees and ~~56,204~~62,586 to its trustees. Units granted to officers and certain employees under the Company’s 2013 Plan are subject to certain performance and market conditions and a three-year service period. Units granted to trustees are subject to certain timing conditions and a two-year service period for full vesting. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend.

Approximately 30% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan in ~~2022~~2023 vest based on a certain market condition. The awards containing the market condition were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of ~~$30.17~~$18.71 per unit for the March ~~2022~~2023 grant using the following assumptions:


Volatility	~~33.9~~23.4		%
Dividend assumption	reinvested
Expected term in years	~~2.84~~2.83 years
Risk-free rate	~~1.44~~4.70		%
Share price (per share)	$	~~16.37~~14.70

The remaining 70% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan, and 100% of other restricted share units issued to trustees vest based upon certain performance or timing conditions. With respect to the performance and timing conditions of the March ~~2022~~2023 grants, the grant date fair value of ~~$16.37~~$14.70 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March ~~2022~~2023 restricted share units issued to officers and certain employees ~~is $20.51~~was $15.90 per unit.

~~Table of Contents~~

The following is a summary of the activity in the Trust’s restricted share units during the nine months ended September 30, ~~2022:~~2023:


		Executive Awards				Trustee Awards				Executive Awards				Trustee Awards
		Restricted Share Units		Weighted Average Grant Date Fair Value		Restricted Share Units	Weighted Average Grant Date Fair Value			Restricted Share Units		Weighted Average Grant Date Fair Value		Restricted Share Units	Weighted Average Grant Date Fair Value
Non-vested at December 31, 2021		976,570		$	22.59	63,008	$	17.85
Non-vested at December 31, 2022									Non-vested at December 31, 2022	1,046,940		$	21.41	77,992	$	16.60
Granted	Granted	299,019		20.51		64,004	16.67		Granted	355,388		15.90		73,860	14.66
Vested	Vested	(228,649)	(1)	25.27		(41,220)	18.20		Vested	(223,579)	(1)	24.36		(49,890)	16.74

Non-vested at September 30, 2022		1,046,940		$	21.41	85,792	$	16.81
Non-vested at September 30, 2023									Non-vested at September 30, 2023	1,178,749		$	19.19	101,962	$	15.13

(1)Restricted units vested by Company executives in ~~2022~~2023 resulted in the issuance of ~~361,679~~652,851 common shares, less ~~160,573~~290,380 common shares withheld to cover minimum withholding tax obligations.

For the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, the Company recognized non-cash share compensation of ~~$3.3~~$2.6 million and ~~$2.7~~$3.3 million, respectively. For the nine ~~months ended~~month periods ending September 30, ~~2022~~2023 and ~~2021,~~2022, the Company recognized non-cash share compensation of ~~$9.4~~$8.6 million and ~~$8.0~~$9.4 million, respectively. Unrecognized compensation expense aton September 30, ~~2022~~2023 was ~~$14.1~~$11.5 million.

Table of Contents

Note 10. Fair Value Measurements

ASC Topic 820, Fair Value Measurement (“ASC 820”), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value.

In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. As part of the Company’s acquisition process, Level 3 inputs are used to measure the fair value of the assets acquired and liabilities assumed.

The Company’s derivative instruments as of September 30, ~~2022~~2023 consist of ~~one~~four interest rate ~~swap,~~swaps, of which three are designated as cash flow hedges of interest rate risk, as detailed in the Derivative Instruments section of Note 7 (Derivatives) ~~of this report~~ and Note 2 (Summary of Significant Accounting Policies) of ~~Part II, Item 8 (Financial Statements and Supplementary Data) of our 2021 Annual Report.~~this report.

The interest rate ~~swap is~~swaps are not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives.

The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There were no such assets measured at fair value as of September 30, ~~2022.~~2023.

The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs.

~~Table of Contents~~

The following table presents the fair value of the Company’s financial instruments (in thousands):


		September 30, 2022				December 31, 2021					September 30, 2023				December 31, 2022
		Carrying Amount		Fair Value		Carrying Amount		Fair Value			Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:	Assets:									Assets:
Real estate loans receivable, net	Real estate loans receivable, net	$	120,432	$	116,406	$	117,844	$	115,385	Real estate loans receivable, net	$	79,884	$	76,935	$	104,973	$	102,162
Notes receivable, net	Notes receivable, net	$	1,326	$	1,326	$	1,097	$	1,097	Notes receivable, net	$	363	$	363	$	370	$	370
Derivative assets	Derivative assets	$	2,071	$	2,071	$	—	$	—	Derivative assets	$	14,731	$	14,731	$	2,045	$	2,045
Liabilities:	Liabilities:									Liabilities:
Credit facility	Credit facility	$	(262,000)	$	(262,000)	$	(274,000)	$	(274,000)	Credit facility	$	(400,000)	$	(400,000)	$	(193,000)	$	(193,000)
Notes payable	Notes payable	$	(1,475,000)	$	(1,282,653)	$	(1,475,000)	$	(1,554,802)	Notes payable	$	(1,460,000)	$	(1,261,390)	$	(1,475,000)	$	(1,302,767)
Mortgage debt	Mortgage debt	$	(165,178)	$	(163,111)	$	(181,035)	$	(182,189)	Mortgage debt	$	(128,127)	$	(127,628)	$	(164,929)	$	(163,129)
Derivative liabilities		$	—	$	—	$	(452)	$	(452)

Table of Contents

Note 11. Tenant Operating Leases

The Company is a lessor of outpatient medical ~~office buildings~~facilities and other health care facilities. Leases have expirations from ~~2022~~2023 through 2042. As of September 30, ~~2022,~~2023, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries and minimum rental payments for assets classified as held for sale, if applicable, were as follows (in thousands):


2022		$	89,516
2023	2023	356,202		2023	$	92,037
2024	2024	342,641		2024	363,106
2025	2025	321,991		2025	346,518
2026	2026	264,367		2026	289,162
2027				2027	237,149
Thereafter	Thereafter	896,326		Thereafter	818,876
Total	Total	$	2,271,043	Total	$	2,146,848

For the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, the Company recognized ~~$127.4~~$134.5 million and ~~$110.3~~$128.6 million, respectively, of rental and other lease-related income related to our operating leases, of which ~~$36.6~~$39.8 million and ~~$29.2~~$36.6 million, respectively, were variable lease payments. For the nine ~~months ended~~month periods ending September 30, ~~2022~~2023 and ~~2021,~~2022, the Company recognized ~~$381.8~~$397.1 million and ~~$326.0~~$385.8 million, respectively, of rental and other ~~lease-related~~leased-related income ~~related~~with respect to our operating leases, of which ~~$107.5~~$115.2 million and ~~$84.0~~$107.5 million, respectively, were variable lease payments.

Note 12. Rent Expense

The Company leases the rights to parking structures at two of its properties, the air ~~space above~~that one property occupies, and the land upon which 97 of its properties are located from third party ~~land owners~~landowners pursuant to separate leases. In addition, the Company has nine corporate leases, primarily for office space.

The Company’s leases include both fixed and variable rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 92 years remaining, excluding extension options, with a weighted average remaining term of 4443 years.

At the inception of a new lease, the Company establishes an operating or finance lease asset and operating or finance lease liability calculated as the present value of future minimum lease payments. As ~~our~~the Company’s leases do not provide an implicit rate, ~~we calculate~~the Company calculates a discount rate that approximates ~~our~~its incremental borrowing rate available at lease commencement in order to determine the present value of future minimum lease payments. The approximated weighted average discount rate was 4.4% as of September 30, ~~2022.~~2023. There are no operating or finance leases that have not yet commenced that would have a significant impact on the Company’s consolidated balance sheets.

~~Table of Contents~~

As of September 30, ~~2022,~~2023, the future minimum lease obligations under non-cancelable parking, air, ground, and corporate leases were as follows (in thousands):


2022		$	1,160
2023	2023	4,798		2023	$	1,261
2024	2024	4,770		2024	5,129
2025	2025	4,751		2025	5,101
2026	2026	4,752		2026	5,090
2027				2027	5,092
Thereafter	Thereafter	243,544		Thereafter	248,386
Total undiscounted lease payments	Total undiscounted lease payments	$	263,775	Total undiscounted lease payments	$	270,059
Less: Interest	Less: Interest	(158,870)		Less: Interest	(165,257)
Present value of lease liabilities	Present value of lease liabilities	$	104,905	Present value of lease liabilities	$	104,802

Table of Contents

Lease costs consisted of the following for the nine months ended September 30, ~~2022~~2023 (in thousands):

Fixed lease cost

~~2,476~~2,480

Variable lease cost

~~959~~1,007

Total lease cost

~~3,435~~3,487

Note 13. Credit Concentration

The Company uses ~~gross leasable area~~annualized base rent (“~~GLA”~~ABR”) as its credit concentration metric. ABR is calculated by multiplying contractual base rent for the month ended September 30, 2023 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of September 30, ~~2022:~~2023 (in thousands):


Tenant	Tenant	Total Leased GLA	Percent of Leased GLA		Tenant	Total ABR		Percent of ABR
CommonSpirit - CHI - Nebraska	CommonSpirit - CHI - Nebraska	899,928	6.1	%	CommonSpirit - CHI - Nebraska	$	18,666	5.1	%
Northside Hospital	Northside Hospital	684,941	4.6	%	Northside Hospital	16,553		4.5	%
UofL Health - Louisville, Inc.	UofL Health - Louisville, Inc.	617,157	4.2	%	UofL Health - Louisville, Inc.	14,656		4.0	%
HonorHealth	HonorHealth	415,791	2.8	%	HonorHealth	11,287		3.1	%
US Oncology	US Oncology	403,751	2.7	%	US Oncology	11,047		3.0	%
Remaining portfolio	Remaining portfolio	11,735,241	79.6	%	Remaining portfolio	295,897		80.3	%
Total	Total	14,756,809	100.0	%	Total	$	368,106	100.0	%

~~GLA~~ABR collected from the Company’s top five tenant relationships comprises ~~20.4%~~19.7% of its total ~~leased GLA~~ABR as of September 30, ~~2022.~~2023. Total ~~GLA~~ABR from ~~CommonSpirit Health affiliated~~CommonSpirit-affiliated tenants totals ~~18.8%~~14.9%, including the ~~affiliates~~affiliate disclosed above.

The following table summarizes certain information about the Company’s top five geographic concentrations as of September 30, ~~2022:~~2023:


State	State	Total GLA	Percent of GLA		State	Total ABR		Percent of ABR
Texas	Texas	1,863,733	12.0	%	Texas	$	49,405	13.4	%
Georgia	Georgia	1,071,182	6.9	%	Georgia	27,099		7.4	%
Florida					Florida	25,495		6.9	%
Indiana	Indiana	1,042,071	6.7	%	Indiana	23,529		6.4	%
Nebraska		981,490	6.3	%
Kentucky		980,639	6.3	%
Arizona					Arizona	21,817		5.9	%
Other	Other	9,594,439	61.8	%	Other	220,761		60.0	%
Total	Total	15,533,554	100.0	%	Total	$	368,106	100.0	%

2122

Table of Contents

Note 14. Earnings Per Share

The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Numerator for earnings per share - basic:	Numerator for earnings per share - basic:									Numerator for earnings per share - basic:
Net income	Net income	$	66,280	$	22,045	$	98,155	$	58,531	Net income	$	12,891	$	66,280	$	36,645	$	98,155
Net income attributable to noncontrolling interests:	Net income attributable to noncontrolling interests:									Net income attributable to noncontrolling interests:
Operating Partnership	Operating Partnership	(3,252)		(529)		(4,830)		(1,405)		Operating Partnership	(505)		(3,252)		(1,443)		(4,830)
Partially owned properties	Partially owned properties	(70)		(152)		(384)		(455)		Partially owned properties	(51)		(70)		(121)		(384)
Preferred distributions		—		—		—		(13)

Numerator for earnings per share - basic	Numerator for earnings per share - basic	$	62,958	$	21,364	$	92,941	$	56,658	Numerator for earnings per share - basic	$	12,335	$	62,958	$	35,081	$	92,941
Numerator for earnings per share - diluted:	Numerator for earnings per share - diluted:									Numerator for earnings per share - diluted:
Numerator for earnings per share - basic	Numerator for earnings per share - basic	$	62,958	$	21,364	$	92,941	$	56,658	Numerator for earnings per share - basic	$	12,335	$	62,958	$	35,081	$	92,941
Noncontrolling interest - Operating Partnership income	Noncontrolling interest - Operating Partnership income	3,252		529		4,830		1,405		Noncontrolling interest - Operating Partnership income	505		3,252		1,443		4,830
Numerator for earnings per share - diluted	Numerator for earnings per share - diluted	$	66,210	$	21,893	$	97,771	$	58,063	Numerator for earnings per share - diluted	$	12,840	$	66,210	$	36,524	$	97,771
Denominator for earnings per share - basic and diluted:	Denominator for earnings per share - basic and diluted:									Denominator for earnings per share - basic and diluted:
Weighted average number of shares outstanding - basic	Weighted average number of shares outstanding - basic	226,529,041		217,406,657		225,743,856		214,616,482		Weighted average number of shares outstanding - basic	238,480,299		226,529,041		238,124,981		225,743,856
Effect of dilutive securities:	Effect of dilutive securities:									Effect of dilutive securities:
Noncontrolling interest - Operating Partnership units	Noncontrolling interest - Operating Partnership units	11,791,685		5,406,070		11,872,328		5,498,046		Noncontrolling interest - Operating Partnership units	9,814,296		11,791,685		9,831,470		11,872,328
Restricted common shares	Restricted common shares	100,790		98,597		105,170		95,999		Restricted common shares	123,801		100,790		127,715		105,170
Restricted share units	Restricted share units	1,476,946		1,080,725		1,424,029		1,189,122		Restricted share units	1,026,916		1,476,946		1,142,747		1,424,029
Denominator for earnings per share - diluted:	Denominator for earnings per share - diluted:	239,898,462		223,992,049		239,145,383		221,399,649		Denominator for earnings per share - diluted:	249,445,312		239,898,462		249,226,913		239,145,383
Earnings per share - basic	Earnings per share - basic	$	0.28	$	0.10	$	0.41	$	0.26	Earnings per share - basic	$	0.05	$	0.28	$	0.15	$	0.41
Earnings per share - diluted	Earnings per share - diluted	$	0.28	$	0.10	$	0.41	$	0.26	Earnings per share - diluted	$	0.05	$	0.28	$	0.15	$	0.41

Note 15. Subsequent Events

On October 29, 2023, the Trust and the Operating Partnership entered into an Agreement and Plan of Merger (the “Merger Agreement”) among the Trust, the Operating Partnership, Healthpeak Properties, Inc. (“Healthpeak”), Alpine Sub, LLC (“Alpine Sub”) and Alpine OP Sub, LLC (“Alpine OP Sub”). The Merger Agreement provides for (a) the merger of the Trust with and into Alpine Sub (the “Company Merger”), with Alpine Sub surviving as a wholly owned subsidiary of Healthpeak (the “Company Surviving Entity”), (b) immediately following the effectiveness of the Company Merger, the contribution by Healthpeak to Healthpeak OP, LLC (“Healthpeak OP”), of all of the outstanding equity interests in the Company Surviving Entity (the “Contribution”) and (c) immediately following the Contribution, the merger of the Operating Partnership with and into Alpine OP Sub (the “Partnership Merger”), with Alpine OP Sub surviving as a subsidiary of Healthpeak OP (the “Partnership Surviving Entity”). The consummation of the Mergers is subject to the satisfaction or waiver of certain closing conditions, including the approval of both the Trust’s and Healthpeak’s shareholders.

Pursuant to the terms and subject to the conditions of the Merger Agreement, at the date and time the Company Merger becomes effective (the “Company Merger Effective Time”), each common share of the Trust (other than common shares to be canceled in accordance with the Merger Agreement), will automatically be converted into the right to receive 0.674 (the “Exchange Ratio”) validly issued, fully paid and non-assessable shares of Healthpeak common stock, par value $1.00 per share (“Healthpeak Common Stock”) (the “Merger Consideration”), without interest, but subject to any withholding required under applicable tax laws. Holders of the Trust’s common shares will receive cash in lieu of fractional shares of Healthpeak Common Stock. Pursuant to the terms and subject to the conditions of the Merger Agreement, immediately after the Contribution and at the date and time the Partnership Merger becomes effective (the “Partnership Merger Effective Time”), each OP Unit issued and outstanding immediately prior to the Partnership Merger Effective Time, subject to the terms and conditions set forth in the Merger Agreement, will automatically be converted into and become a number of units in the Partnership Surviving Entity equal to the Exchange Ratio.

Table of Contents

business in all material respects in the ordinary course, consistent with past practice, and to refrain from taking certain actions without Healthpeak’s consent. Healthpeak has agreed to customary pre-closing covenants, including a more limited set of covenants to refrain from taking certain actions without the Trust’s consent and to use commercially reasonable efforts to carry on its business in all material respects in the ordinary course, consistent with past practice. Each party has agreed to additional covenants, including, among others, covenants relating to (i) the Trust’s obligation to call a meeting of its shareholders to approve the Company Merger, (ii) Healthpeak’s obligation to call a meeting of its stockholders to approve the Healthpeak Common Stock Issuance (as defined in the Merger Agreement) and the Parent Charter Amendment (as defined in the Merger Agreement) and (iii) each party’s non-solicitation obligations related to alternative acquisition proposals. Healthpeak’s board of directors and the Trust’s Board of Trustees each have unanimously approved the Merger Agreement. The Mergers are expected to close during the first half of 2024.

In connection with the Merger Agreement, the Trust suspended the 2023 ATM Program.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our unaudited consolidated financial statements, including the notes to those statements, included in Part I, Item 1 of this report, and the Section entitled “Cautionary Statement Regarding Forward-Looking Statements” in this report. As discussed in more detail in the Section entitled “Cautionary Statement Regarding Forward-Looking Statements,” this discussion contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause those differences include those discussed in Part I, Item 1 (Business) and Part I, Item 1A (Risk Factors) of our ~~2021~~2022 Annual ~~Report.~~Report and Part II, Item 1A of this report.

Third Quarter Highlights:

•Reported third quarter ~~2022~~2023 total revenue of ~~$131.5~~$138.5 million, an increase of ~~14.1%~~5.3% over the prior year period.

•~~Generated~~Reported net income of $12.9 million for the quarter ended September 30, 2023, a decrease of 80.6% over the prior year period, and third quarter net income per share of ~~$0.28~~$0.05 on a fully diluted ~~basis, compared to~~basis. Net income in the third quarter 2022 included a $53.9 million net ~~income per share~~gain on the sale of ~~$0.10 for the same period last year.~~investment properties.

•Generated third quarter Normalized Funds From Operations ~~(Normalized FFO)~~(“Normalized FFO”) of ~~$0.26~~$0.25 per share on a fully diluted ~~basis, consistent with the same period last year.~~basis.

•Completed ~~$101.7~~$16.8 million ofin investments, including the funding of previous ~~construction~~ loan ~~commitments during the third quarter.~~commitments.

•Third quarter ~~MOB~~Outpatient Medical Same-Store Cash Net Operating Income growth was ~~1.1%~~1.5% year-over-year.

•Declared a quarterly dividend of $0.23 per share and OP Unit for the third quarter ~~2022,~~2023, paid on October ~~14, 2022.~~

•~~Disposed of three related properties in Great Falls, Montana for $116.3 million and recognized a net gain on the sale of approximately $53.9 million.~~

•~~Sold 440,400 common shares pursuant to the ATM program at a weighted average price of $18.15 during the third quarter, resulting in net proceeds of $7.9 million.~~

~~Subsequent Event Highlights:~~

•~~Earned a score of 75 out of 100 and a Green Star designation in the 2022 GRESB Real Estate Assessment and a score of 98 out of 100 and an “A” rating for its GRESB Public Disclosure Level.~~17, 2023.

Overview

We are a self-managed health care real estate company organized in April 2013 to acquire, selectively develop, own, and manage health care properties that are leased to physicians, hospitals, and health care delivery systems. We invest in real estate that is integral to providing high quality health care services. Our properties are typically located on a campus with a hospital or other health care facilities or strategically affiliated with a hospital or other health care facilities. We believe the impact of government programs and continuing trends in the health care industry create attractive opportunities for us to invest in health care related real estate. In particular, we believe the demand for health care will continue to increase as a result of the aging population as older persons generally utilize health care services at a rate well in excess of younger people. Our management team has significant public health care REIT experience and has long-established relationships with physicians, hospitals, and health care delivery system decision makers that we believe will provide quality investment and growth opportunities. Our principal investments include outpatient medical ~~office buildings,~~facilities, outpatient treatment facilities, as well as other real estate integral to health care providers. In recent years, we have seen increased competition for health care properties, and we expect this trend to continue. We seek to generate attractive risk-adjusted returns for our shareholders through a combination of stable and increasing dividends and potential long-term appreciation in the value of our properties and our common shares.

We grew our portfolio of gross real estate investments from approximately $124 million at the time of our IPO in July 2013 to approximately ~~$5.8~~$5.9 billion as of September 30, ~~2022.~~2023. As of September 30, ~~2022,~~2023, our consolidated portfolio consisted of ~~277~~278 health care properties located in 32 states with approximately ~~15,533,554~~15,644,254 net leasable square feet, which were approximately 95% leased with a weighted average remaining lease term of approximately ~~5.7~~5.3 years. As of September 30, ~~2022,~~2023, approximately ~~90%~~91% of the net leasable square footage of our portfolio was either on the campus of a hospital or strategically affiliated with a health system.

We receive a cash rental stream from the health care providers under our leases. Approximately ~~95%~~93% of the annualized base rent payments from our properties as of September 30, ~~2022 are~~2023 were from absolute net and ~~triple-net~~triple net leases, pursuant to which the tenants are responsible for operating expenses subject to specific lease terms relating to the property, including but not limited to real estate taxes, utilities, property insurance, routine maintenance and repairs, and property management. This structure helps insulate us from increases in certain operating expenses and provides more predictable cash flow. Approximately 4%6% of the ~~annualized base rent~~ABR payments

~~Table of Contents~~

from our properties as of September 30, ~~2022 are~~2023 were from modified gross ~~base stop~~ leases which allow us to pass through certain increases in future operating expenses (e.g., property tax and insurance) to tenants for reimbursement, thus protecting us from increases in such operating expenses.

We seek to structure our triple-net leases to generate attractive returns on a long-term basis. Our leases typically have initial terms of 5 to 15 years and include annual rent escalators of approximately 1.5% to 4.0%, with an annual weighted average rent escalator of approximately 2.4%. ~~Certain~~However, certain of the Company’s leases ~~include provisions indexing~~contain annual rent escalators indexed to changes in the Consumer Price Index (“CPI”), often with a floor or ceiling. As of September 30, ~~2022,~~2023, approximately ~~5.6%~~5.8% of the Company’s annual rent escalators ~~have~~had CPI provisions. Our operating results depend significantly upon the ability of our

Table of Contents

tenants to make required rental payments. We believe that our portfolio of outpatient medical ~~office buildings~~facilities and other health care facilities will enable us to generate stable cash flows over time because of the diversity of our tenants, staggered lease expiration schedule, long-term leases, and low historical occurrence of tenants defaulting under their leases. As of September 30, ~~2022,~~2023, leases representing approximately 1.0%, ~~4.7%~~5.6%, and ~~6.2%~~6.9% of leased square feet will expire in ~~2022,~~ 2023, 2024, and ~~2024,~~2025, respectively.

WeSubject to the restrictions in the Merger Agreement, we intend to grow our portfolio of high-quality ~~health care properties~~outpatient medical facilities leased to physicians, hospitals, health care delivery systems, and other health care providers primarily through acquisitions of existing health care facilities that provide stable revenue growth and predictable long-term cash flows. We may also selectively finance, subject to the restrictions in the Merger Agreement, the development or redevelopment of new health care facilities through joint venture or fee arrangements with health care real estate developers or health system development professionals. Generally, we expect to make investments in new development properties when approximately 80% or more of the development property has been pre-leased before construction commences. We seek to invest in properties where we can develop strategic alliances with financially sound health care providers and health care delivery systems that offer need-based health care services in sustainable health care markets. We focus our investment activity on outpatient medical ~~office buildings~~facilities and ambulatory surgery centers.

We believe that trends such as shifting consumer preferences, limited space in hospitals, the desire of patients and health care providers to limit non-essential services provided in a hospital setting, and cost considerations, continue to drive the industry towards performing more procedures in outpatient facilities versus the hospital setting. As these trends continue, we believe that demand for outpatient medical ~~office buildings~~facilities and similar health care properties away from hospital settings and in convenient locations to patients will continue to rise. We intend to exploit this trend and seek outpatient properties consistent with our investment philosophy and strategies.

While not our focus, we may choose to invest opportunistically in life science facilities, senior housing properties, skilled nursing facilities, specialty hospitals, behavioral health facilities, and treatment centers. Consistent with our qualification as a REIT, we may also opportunistically invest in companies that provide health care services, and in joint venture entities with operating partners, structured to comply with the REIT Investment Diversification Act of 2007.

The Trust is a Maryland real estate investment trust and elected to be taxed as a REIT for U.S. federal income tax purposes. We conduct our business through an UPREIT structure in which our properties are owned by our Operating Partnership directly or through limited partnerships, limited liability companies, or other subsidiaries. The Trust is the sole general partner of our Operating Partnership and, as of September 30, ~~2022,~~2023, owned approximately ~~95.1%~~96.1% of the OP Units. As of October ~~26, 2022,~~27, 2023, there were ~~228,260,860~~238,487,448 common shares outstanding.

Key Transactions in Third Quarter ~~2022~~2023

Investment Activity

During the ~~three months~~third quarter ended September 30, ~~2022,~~2023, the Company completed the acquisition of one outpatient medical ~~office~~ facility and a parcel of land adjacent to one of our existing properties for an aggregate purchase price of ~~$81.5~~$3.5 million. Additionally, the Company funded an aggregate $5.9 million and the funding of two term loans for $14.1 million, $0.6 million of a previously announced term loan, and $0.4 million of previous construction loan commitments. The Company also paid $5.0 million of additional purchase consideration under two earn-out agreements, previously announced loan commitments, and ~~invested $0.3~~other investments, including an $1.3 million investment in ~~funds managed by a real estate technology private equity fund,~~IJRI Properties, LLC, which is an entity constructing and operating an outpatient medical facility in Indiana. The Company also funded construction in progress of $7.4 million, resulting in total investment activity of approximately ~~$101.7~~$16.8 million as of September 30, ~~2022.~~2023.

During the three months ended September 30, 2022, the Company sold three related facilities, which included two medical office buildings and one hospital, representing 185,085 square feet for approximately $116.3 million, realizing an aggregate net gain of approximately $53.9 million.

~~Table of Contents~~

Recent Developments

Quarterly Distribution

On September ~~23, 2022,~~21, 2023, we announced that our Board of Trustees authorized and declared a cash distribution of $0.23 per common share for the quarterly period ended September 30, ~~2022.~~2023. The dividend was paid on October ~~14, 2022~~17, 2023, to common shareholders and OP Unit holders of record as of the close of business on October ~~4, 2022.~~3, 2023.

Table of Contents

Recent Events

On October 29, 2023, the Trust and the Operating Partnership entered into the Merger Agreement among the Trust, the Operating Partnership, Healthpeak, Alpine Sub and Alpine OP Sub. The Merger Agreement provides for (a) the Company ~~did not suffer~~Merger, (b) immediately following the effectiveness of the Company Merger, the Contribution and (c) immediately following the Contribution, the Partnership Merger. The consummation of the Mergers is subject to the satisfaction or waiver of certain closing conditions, including the approval of both the Trust’s and Healthpeak’s shareholders.

Pursuant to the terms and subject to the conditions of the Merger Agreement, at the Company Merger Effective Time, each common share of the Trust (other than common shares to be canceled in accordance with the Merger Agreement), will automatically be converted into the right to receive the Merger Consideration, without interest, but subject to any withholding required under applicable tax laws. Holders of the Trust’s common shares will receive cash in lieu of fractional shares of Healthpeak Common Stock. Pursuant to the terms and subject to the conditions of the Merger Agreement, at the Partnership Merger Effective Time, each OP Unit issued and outstanding immediately prior to the Partnership Merger Effective Time, subject to the terms and conditions set forth in the Merger Agreement, will automatically be converted into and become a number of units in the Partnership Surviving Entity equal to the Exchange Ratio.

The Merger Agreement contains customary representations and warranties from each of Healthpeak and the Trust. The Trust has agreed to customary pre-closing covenants, including covenants to use commercially reasonable efforts to carry on its business in all material ~~losses~~respects in the ordinary course, consistent with past practice, and to refrain from taking certain actions without Healthpeak’s consent. Healthpeak has agreed to customary pre-closing covenants, including a more limited set of covenants to refrain from taking certain actions without the Trust’s consent and to use commercially reasonable efforts to carry on its business in all material respects in the ordinary course, consistent with past practice. Each party has agreed to additional covenants, including, among others, covenants relating to (i) the Trust’s obligation to call a meeting of its shareholders to approve the Company Merger, (ii) Healthpeak’s obligation to call a meeting of its stockholders to approve the Healthpeak Common Stock Issuance and the Parent Charter Amendment and (iii) each party’s non-solicitation obligations related to ~~Hurricane Ian. We own 12 properties, representing approximately 673,000 square feet, in~~alternative acquisition proposals. Healthpeak’s board of directors and the ~~path~~Trust’s Board of Trustees each have unanimously approved the ~~storm and experienced minimal operational disruptions~~Merger Agreement. The Mergers are expected to close during the first half of 2024.

In connection with ~~no impact on rent collection from any of our tenants.~~the Merger Agreement, the Trust suspended the 2023 ATM Program.

Results of Operations

Three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021.~~2022.

The following table summarizes our results of operations for the three months ended September 30, ~~2022~~2023 and ~~2021~~2022 (in thousands):


		2022		2021		Change		%			2023		2022		Change		%
Revenues:	Revenues:									Revenues:
Rental and related revenues	Rental and related revenues	$	127,381	$	110,314	$	17,067	15.5	%	Rental and related revenues	$	134,520	$	128,636	$	5,884	4.6	%
Interest income on real estate loans and other	Interest income on real estate loans and other	4,132		4,997		(865)		(17.3)	%	Interest income on real estate loans and other	4,027		2,877		1,150		40.0	%
Total revenues	Total revenues	131,513		115,311		16,202		14.1	%	Total revenues	138,547		131,513		7,034		5.3	%
Expenses:	Expenses:									Expenses:
Interest expense	Interest expense	18,299		13,498		4,801		35.6	%	Interest expense	20,050		18,299		1,751		9.6	%
General and administrative	General and administrative	10,079		9,534		545		5.7	%	General and administrative	9,771		10,079		(308)		(3.1)	%
Operating expenses	Operating expenses	43,647		35,679		7,968		22.3	%	Operating expenses	47,625		43,647		3,978		9.1	%
Depreciation and amortization	Depreciation and amortization	47,040		38,582		8,458		21.9	%	Depreciation and amortization	47,932		47,040		892		1.9	%
Impairment loss		—		340		(340)		NM

Total expenses	Total expenses	119,065		97,633		21,432		22.0	%	Total expenses	125,378		119,065		6,313		5.3	%
Income before equity in loss of unconsolidated entities and gain on sale of investment properties, net:	Income before equity in loss of unconsolidated entities and gain on sale of investment properties, net:	12,448		17,678		(5,230)		(29.6)	%	Income before equity in loss of unconsolidated entities and gain on sale of investment properties, net:	13,169		12,448		721		5.8	%
Equity in loss of unconsolidated entities	Equity in loss of unconsolidated entities	(62)		(390)		328		84.1	%	Equity in loss of unconsolidated entities	(278)		(62)		(216)		348.4	%
Gain on sale of investment properties, net	Gain on sale of investment properties, net	53,894		4,757		49,137		NM		Gain on sale of investment properties, net	—		53,894		(53,894)		NM
Net income	Net income	$	66,280	$	22,045	$	44,235	200.7	%	Net income	$	12,891	$	66,280	$	(53,389)	(80.6)	%

NM = Not Meaningful

Table of Contents

Revenues

Total revenues increased ~~$16.2~~$7.0 million, or ~~14.1%~~5.3%, for the three months ended September 30, ~~2022~~2023 as compared to the three months ended September 30, ~~2021.~~2022. An analysis of selected revenues follows.

Rental and related revenues. Rental and related revenues increased ~~$17.1~~$5.9 million, or ~~15.5%~~4.6%, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021.~~2022. Rental and related revenues were comprised of the following based upon contractual billing terms (in thousands):


		2022		2021		Change		%			2023		2022		Change		%
Rental revenues	Rental revenues	$	90,818	$	81,096	$	9,722	12.0	%	Rental revenues	$	94,744	$	92,073	$	2,671	2.9	%
Expense recoveries	Expense recoveries	36,563		29,218		7,345		25.1	%	Expense recoveries	39,776		36,563		3,213		8.8	%
Rental and related revenues	Rental and related revenues	$	127,381	$	110,314	$	17,067	15.5	%	Rental and related revenues	$	134,520	$	128,636	$	5,884	4.6	%

~~Table of Contents~~

Rental revenues increased ~~$9.7~~$2.7 million, or ~~12.0%~~2.9%, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021.~~2022. Rental revenues increased ~~$13.0~~$1.9 million from properties acquired in 2023 and 2022, and ~~2021, including $9.6~~$1.0 million ~~related to the 14 medical office buildings acquired on December 20, 2021~~ from ~~Landmark Healthcare Facilities LLC (the “Landmark Portfolio”). These increases were~~our existing portfolio. This increase was partially offset by a decrease of ~~$2.7~~$0.3 million related to properties sold in ~~2022~~2023 and ~~2021 and $0.5 million related to net decreases on our existing portfolio due to move outs.~~2022.

Expense recoveries increased ~~$7.3~~$3.2 million, or ~~25.1%~~8.8%, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021.~~2022. Expense recoveries increased ~~$7.0~~$2.4 million due to higher reimbursable operating expenses on our existing portfolio and $0.8 million from properties acquired in ~~2022~~2023 and 2021, including $5.4 million related to the Landmark Portfolio in 2021, and $0.7 million due to an increase in reimbursable operating expenses from our existing portfolio, explained below. These increases were partially offset by a decrease of $0.1 million related to properties sold in 2022 and 2021.2022.

Interest income on real estate loans and other. Interest income on real estate loans and other ~~decreased $0.9~~increased $1.2 million, or ~~17.3%~~40.0%, for the three months ended September 30, ~~2022~~2023 as compared to the three months ended September 30, ~~2021.~~2022. Interest income on real estate loans and other ~~decreased $1.3~~increased by $2.3 million due to interest earned on the remaining proceeds of $214.0 million from our $400.0 million term loan which was entered into in the second quarter of 2023. This increase was partially offset by a decrease of $0.9 million related to lower average real estate loan balances in ~~2022~~2023 compared to ~~2021. This was offset by~~2022, and $0.2 million of non-cash changes in the fair value of an ~~increase in income due to tenant improvement and capital expenditures of $0.4 million.~~interest rate swap.

Expenses

Total expenses increased ~~$21.4~~$6.3 million, or ~~22.0%~~5.3%, for the three months ended September 30, ~~2022~~2023 as compared to the three months ended September 30, ~~2021.~~2022. An analysis of selected expenses follows.

Interest expense. Interest expense increased ~~$4.8~~$1.8 million, or ~~35.6%~~9.6%, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021. The issuance~~2022. Interest expense increased $6.5 million from the $400.0 million term loan executed on May 24, 2023, and $0.6 million from increasing interest rates on our variable mortgage debt. This growth was partially offset by a $1.8 million reduction due to the derecognition of ~~the 2031 Senior Notes resulted in~~ an ~~increase of $3.4 million, new mortgage debt resulted in an increase of $1.4 million, a higher effective~~ interest rate swap, $1.7 million of proceeds from the Company’s outstanding interest rate swaps, and a decrease of $1.7 million due to lower debt balances on our credit facility resulted in an increase of $1.1 million, and higher debt balances resulted in an increase of $0.3 million. Our weighted average effective interest rate on our credit facility was 3.0% and 1.0% for three months ended September 30, 2022 and 2021, respectively. These increases were partially offset by the October 2021 pay off and extinguishment of our $250.0 million term loan feature of the Credit Agreement and the associated pay-fixed receive-variable rate swaps, which resulted in a decrease of $0.7 million and $0.7 million, respectively.facility.

General and administrative. General and administrative expenses ~~increased $0.5~~decreased $0.3 million, or ~~5.7%~~3.1%, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021.~~2022. The ~~increase~~decrease was primarily due to ~~higher non-cash compensation of $0.7 million. These increases were partially offset by~~ lower ~~marketing~~travel costs of ~~$0.1~~$0.3 million.

Operating expenses. Operating expenses increased ~~$8.0~~$4.0 million, or ~~22.3%~~9.1%, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021. Net operating expenses from properties acquired in 2022 and 2021 increased by $7.4 million, including $5.8 million related to the Landmark Portfolio in 2021.~~2022. Operating expenses on the existing portfolio increased by ~~$0.7~~$3.1 million, or ~~2.0%~~7.1% quarter over quarter, mainly due to higher ~~utility costs of $1.4 million and~~ maintenance costs of ~~$0.4~~$1.7 million ~~which were partially offset by lower~~and real estate taxes of ~~$0.9 million~~$1.2 million. Operating expenses from properties acquired in 2023 and ~~lower insurance costs of $0.3~~2022 increased by $1.0 million.

Depreciation and amortization. Depreciation and amortization increased ~~$8.5~~$0.9 million, or ~~21.9%~~1.9%, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021.~~2022. Depreciation and amortization increased ~~$10.2~~$0.9 million for properties purchased in ~~2022~~2023 and 2021, including $7.6 million related to the Landmark Portfolio in 2021. These increases were partially offset by $1.2 million related to properties sold during 2022 and 2021 and $0.6 million related to our existing portfolio due to fully amortized lease intangibles.

~~Impairment loss.~~ During the three months ended September 30, 2021, the Company recorded an impairment charge of $0.3 million related to a medical office building in Traverse City, Michigan. The Company did not record any impairment loss during the three months ended September 30, 2022.

Equity in loss of unconsolidated entities. ~~The change in equity~~Equity in loss of unconsolidated entities increased $0.2 million, for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021 is primarily~~2022 due to a decrease in revenue related to property dispositions within our ~~additional investments~~unconsolidated joint venture portfolio and an increase in ~~the Davis Joint Venture.~~

operating expenses.

2628

Table of Contents

Gain on sale of investment properties, net.During the three months ended September 30, 2022, we sold three related facilities, which included two outpatient medical ~~office buildings~~facilities and one hospital in Great Falls, Montana, representing 185,085 square feet for approximately $116.3 million, realizing an aggregate net gain of approximately $53.9 million. During the three months ended September 30, 2021, we sold two properties representing 93,332 net leasable square feet located in Indiana for approximately $27.4 million, realizing a net gain of approximately $4.8 million.

Nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022.

The following table summarizes our results of operations for the nine months ended September 30, ~~2022~~2023 and ~~2021~~2022 (in thousands):


		2022		2021		Change		%			2023		2022		Change		%
Revenues:	Revenues:									Revenues:
Rental and related revenues	Rental and related revenues	$	381,785	$	326,017	$	55,768	17.1	%	Rental and related revenues	$	397,096	$	385,755	$	11,341	2.9	%
Interest income on real estate loans and other	Interest income on real estate loans and other	12,285		15,558		(3,273)		(21.0)	%	Interest income on real estate loans and other	10,895		8,315		2,580		31.0	%
Total revenues	Total revenues	394,070		341,575		52,495		15.4	%	Total revenues	407,991		394,070		13,921		3.5	%
Expenses:	Expenses:									Expenses:
Interest expense	Interest expense	52,356		40,754		11,602		28.5	%	Interest expense	59,837		52,356		7,481		14.3	%
General and administrative	General and administrative	30,400		28,116		2,284		8.1	%	General and administrative	31,133		30,400		733		2.4	%
Operating expenses	Operating expenses	128,080		103,069		25,011		24.3	%	Operating expenses	138,094		128,080		10,014		7.8	%
Depreciation and amortization	Depreciation and amortization	142,002		114,663		27,339		23.8	%	Depreciation and amortization	143,555		142,002		1,553		1.1	%

Impairment loss		—		340		(340)		NM

Total expenses	Total expenses	352,838		286,942		65,896		23.0	%	Total expenses	372,619		352,838		19,781		5.6	%
Income before equity in loss of unconsolidated entities and gain on sale of investment properties, net:		41,232		54,633		(13,401)		(24.5)	%
Equity in loss of unconsolidated entities		(452)		(1,213)		761		62.7	%
Income before equity in gain (loss) of unconsolidated entities and gain on sale of investment properties, net:										Income before equity in gain (loss) of unconsolidated entities and gain on sale of investment properties, net:	35,372		41,232		(5,860)		(14.2)	%
Equity in gain (loss) of unconsolidated entities										Equity in gain (loss) of unconsolidated entities	1,260		(452)		1,712		378.8	%
Gain on sale of investment properties, net	Gain on sale of investment properties, net	57,375		5,111		52,264		NM		Gain on sale of investment properties, net	13		57,375		(57,362)		NM
Net income	Net income	$	98,155	$	58,531	$	39,624	67.7	%	Net income	$	36,645	$	98,155	$	(61,510)	(62.7)	%

Revenues

Total revenues increased ~~$52.5~~$13.9 million, or ~~15.4%~~3.5%, for the nine months ended September 30, ~~2022~~2023 as compared to the nine months ended September 30, ~~2021.~~2022. An analysis of selected revenues follows.

Rental and related revenues. Rental and related revenues increased ~~$55.8~~$11.3 million, or ~~17.1%~~2.9%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022. Rental and related revenues were comprised of the following based on contractual billing terms (in thousands):


		2022		2021		Change		%			2023		2022		Change		%
Rental revenues	Rental revenues	$	274,260	$	242,062	$	32,198	13.3	%	Rental revenues	$	281,901	$	278,230	$	3,671	1.3	%
Expense recoveries	Expense recoveries	107,525		83,955		23,570		28.1	%	Expense recoveries	115,195		107,525		7,670		7.1	%
Rental and related revenues	Rental and related revenues	$	381,785	$	326,017	$	55,768	17.1	%	Rental and related revenues	$	397,096	$	385,755	$	11,341	2.9	%

Rental revenues increased ~~$32.2~~$3.7 million, or ~~13.3%~~1.3%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022. Rental revenues increased ~~$39.1~~$5.2 million from properties acquired in 2023 and 2022, and ~~2021, including $28.5~~$1.8 million ~~related to the Landmark Portfolio in 2021.~~from our existing portfolio. This increase was partially offset by a decrease of ~~$6.4~~$3.2 million related to properties sold in ~~2022 and 2021 and $0.5 million related to net decreases on our existing portfolio due to move outs.~~2022.

Expense recoveries increased ~~$23.6~~$7.7 million, or ~~28.1%~~7.1%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022. Expense recoveries increased ~~$19.5 million from properties acquired in 2022 and 2021, including $14.6 million related to the Landmark Portfolio in 2021, and $4.5~~$5.4 million due to an increase in reimbursable operating expenses from our existing portfolio, ~~explained below. These increases were partially offset by $0.2~~and $2.4 million ~~related to~~from properties ~~sold~~acquired in ~~2022~~2023 and ~~2021.~~2022.

~~Table of Contents~~

Interest income on real estate loans and other. Interest income on real estate loans and other ~~decreased $3.3~~increased $2.6 million, or ~~21.0%~~31.0%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022. Interest income on real estate loans and other ~~decreased $4.8~~increased by $3.3 million due to interest earned on the remaining proceeds of $214.0 million from our new $400.0 million term loan. This was offset by a decrease $0.6 million due to lower average real estate loan balances in ~~2022~~2023 compared to ~~2021. This was offset by an increase in income due to tenant improvement and capital expenditures~~2022.

Table of ~~$1.6 million.~~Contents

Expenses

Total expenses increased by ~~$65.9~~$19.8 million, or ~~23.0%~~5.6%, for the nine months ended September 30, ~~2022~~2023 as compared to the nine months ended September 30, ~~2021.~~2022. An analysis of selected expenses follows.

Interest expense. Interest expense increased ~~$11.6~~$7.5 million, or ~~28.5%~~14.3%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021. The issuance of~~2022. Interest expense increased $9.1 million from the ~~2031 Senior Notes resulted in an increase of $10.2~~$400.0 million ~~new mortgage debt resulted in an increase of~~term loan executed on May 24, 2023, and $3.2 million ~~and increased borrowings~~from increasing interest rates on our ~~credit facility resulted in an increase of $1.9 million.~~variable mortgage debt. These increases were partially offset by ~~the October 2021 pay off and extinguishment~~favorable effects of our ~~$250.0 million term loan feature of the Credit Agreement and the associated pay-fixed receive-variable~~interest rate swaps, ~~which resulted in a decrease~~including $1.8 million due to the de-designation of ~~$2.1 million and $1.7 million, respectively.~~an interest rate swap.

General and administrative. General and administrative expenses increased ~~$2.3~~$0.7 million, or ~~8.1%~~2.4%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022. The increase was primarily attributable to increased ~~non-cash compensation~~professional fees of ~~$1.6 million and higher travel and marketing costs of $0.7~~$0.8 million.

Operating expenses. Operating expenses increased ~~$25.0~~$10.0 million, or ~~24.3%~~7.8%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021. Net operating expenses from properties acquired in 2022 and 2021 increased by $20.9 million, including $15.8 million related to the Landmark Portfolio in 2021.~~2022. Operating expenses on the existing portfolio increased by ~~$4.5~~$7.5 million, or ~~4.5%~~5.9% year over year, mainly due to additional ~~utility charges of $3.0 million and~~ building maintenance costs of ~~$1.8~~$4.3 million, ~~partially offset by~~property administration costs of $1.3 million, insurance expense ~~decreases~~ of ~~$0.3~~$1.1 million, and utility charges of $0.6 million. Net operating expenses from properties acquired in 2023 and 2022 also increased by $2.6 million.

Depreciation and amortization. Depreciation and amortization increased ~~$27.3~~$1.6 million, or ~~23.8%~~1.1%, for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022. Depreciation and amortization increased ~~$31.4~~$3.3 million for properties purchased in ~~2022~~2023 and ~~2021, including $23.0 million related to the Landmark Portfolio in 2021.~~2022. These increases were partially offset by ~~$2.8~~$1.0 million from properties sold during 2023 and 2022, and ~~2021 and an additional decrease of $1.2~~$0.6 million from our existing portfolio primarily due to fully amortized lease intangibles.

~~Impairment loss.~~ During the nine months ended September 30, 2021, the Company recorded an impairment charge of $0.3 million related to a medical office building in Traverse City, Michigan. The Company did not record any impairment loss during the nine months ended September 30, 2022.

Equity in ~~loss~~gain (loss) of unconsolidated entities. The ~~$0.8~~$1.7 million change in equity in ~~loss~~gain (loss) of unconsolidated entities for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021~~2022 is primarily due to a $1.8 million gain on our ~~additional investments in~~share of the ~~Davis Joint Venture.~~sale of two assets held within our unconsolidated joint venture portfolio.

Gain on sale of investment properties, net. During the nine months ended September 30, 2023, we sold one property in Pennsylvania containing 30,000 square feet for approximately $2.6 million, realizing an insignificant gain. During the nine months ended September 30, 2022, we sold five properties ~~representing~~with 212,295 net leasable square feet ~~located~~ in three states for approximately $124.7 million, realizing a net gain of approximately $57.4 million. During the nine months ended September 30, 2021, across four states we sold four properties with 157,221 net leasable square feet and three parcels of vacant land for approximately $31.7 million, recognizing a net gain of ~~$5.1~~$57.4 million.

Cash Flows

Nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021~~2022 (in thousands).


		2022		2021			2023		2022
Cash provided by operating activities	Cash provided by operating activities	$	202,353	$	175,747	Cash provided by operating activities	$	205,912	$	202,353
Cash used in investing activities	Cash used in investing activities	(41,680)		(118,965)		Cash used in investing activities	(64,723)		(41,680)
Cash used in financing activities		(168,037)		(53,931)
(Decrease) increase in cash and cash equivalents		$	(7,364)	$	2,851
Cash provided by (used in) financing activities						Cash provided by (used in) financing activities	46,853		(168,037)
Increase (decrease) in cash and cash equivalents						Increase (decrease) in cash and cash equivalents	$	188,042	$	(7,364)

~~Table of Contents~~

Cash flows from operating activities. Cash flows provided by operating activities ~~was~~were $205.9 million during the nine months ended September 30, 2023 compared to $202.4 million during the nine months ended September 30, 2022, ~~compared to $175.7 million during the nine months ended September 30, 2021,~~ representing an increase of ~~$26.6~~$3.6 million. ~~Net~~The increase in cash provided by operating activities ~~increased~~is primarily due to the ~~impact~~timing of payment on our ~~2022~~tenant receivables and ~~2021 acquisitions, including the Landmark Portfolio,~~accrued expenses and ~~contractual rent increases. These increases were partially offset by the impact of our 2022 and 2021 dispositions.~~other liabilities.

Cash flows from investing activities. Cash flows used in investing activities was $64.7 million during the nine months ended September 30, 2023 compared to $41.7 million during the nine months ended September 30, 2022, ~~compared to cash flows used in investing activities~~representing an increase of ~~$119.0 million during the nine months ended September 30, 2021, representing a~~$23.0 million. The change ~~of $77.3 million.The decrease~~ in cash ~~flows~~ used in investing activities was primarily due to the decrease in proceeds ~~on sales~~from the sale of investment properties ~~which increased cash by $92.1~~of $120.6 million and aan increase of net ~~decrease of $4.5 million of~~ cash spent on the ~~acquisitions~~development of ~~investment properties~~real estate and ~~unconsolidated entities.~~capital expenditures of $14.0 million. This was partially offset by less cash spent on the acquisition of investments of $81.6 million, additional returns on our investment in unconsolidated entities of $3.7 million, and net real estate loan payoffs which provided an increase in ~~net investments in real estate loan receivables~~cash of ~~$11.7 million and cash spent on capital expenditures which increased by $7.7~~$26.0 million.

Table of Contents

Cash flows from financing activities. Cash flows provided by financing activities was $46.9 million during the nine months ended September 30, 2023 compared to cash flows used in financing activities ~~was~~of $168.0 million during the nine months ended September 30, 2022, ~~compared to $53.9 million during the nine months ended September 30, 2021,~~ representing ~~an increase~~a change of ~~$114.1~~$214.9 million. The change in cash ~~used in~~provided by financing activities was primarily due to ~~a decrease~~an increase in ~~net~~ proceeds from credit facility borrowings of $274.0 million, an increase in the sale of common shares pursuant to the ATM Program of ~~$103.7~~$34.5 million, an increase in contributions from noncontrolling interests of $7.6 million, a decrease of distributions to noncontrolling interests of $1.4 million, and a decrease in the purchase of OP Units of $2.3 million. These sources of cash were partially offset by an increase in paydowns under the credit facility of $55.0 million, the repayment of senior unsecured notes and mortgage debt of $36.0 million, an increase of dividends paid to shareholders of ~~$8.4~~$8.6 million, an increase in 2022 compared to 2021, and $8.0 million of additional principal payments made on mortgage debt. Further, $4.4 million of additional distributions were paid to noncontrolling interests of the operating partnership and net paydowns under the credit facility increased by $5.0 million. These increases were partially offset by a decrease of $5.2 million related to debt issuance costs ~~and a decrease in cash used in the redemption~~ of ~~Series A Preferred Units of $4.7 million, as no redemptions were made in 2022. Further, cash used in the redemption of OP Units decreased $3.0 million, payments made on financing leases decreased $1.7~~$3.8 million, and ~~preferred distributions made to OP unit holders decreased $0.3 million.~~an increase of $1.6 million for payments of employee taxes withheld for stock-based compensation.

Non-GAAP Financial Measures

This report includes Funds From Operations ~~(FFO)~~(“FFO”), Normalized FFO, Normalized Funds Available For Distribution ~~(FAD)~~(“FAD”), Net Operating Income ~~(NOI)~~(“NOI”), Cash NOI, ~~MOB~~Outpatient Medical Same-Store Cash NOI, Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate ~~(EBITDA~~(“EBITDArere”) and Adjusted EBITDAre, which are non-GAAP financial measures. For purposes of Item 10(e) of Regulation S-K promulgated under the Securities Act, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this report, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Item 10(e) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the Securities Act”), we have provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

FFO and Normalized FFO

We believe that information regarding FFO is helpful to shareholders and potential investors because it facilitates an understanding of the operating performance of our properties without giving effect to real estate depreciation and amortization, which assumes that the value of real estate assets diminishes ratably over time. We calculate FFO in accordance with standards established by the National Association of Real Estate Investment Trusts ~~(Nareit)~~(“Nareit”). Nareit defines FFO as net income or loss (computed in accordance with GAAP) before noncontrolling interests of holders of OP units, excluding preferred distributions, gains (or losses) on sales of depreciable operating property, impairment write-downs on depreciable assets, plus real estate related depreciation and amortization (excluding amortization of deferred financing costs). Our FFO computation includes our share of required adjustments from our unconsolidated joint ventures and may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the Nareit definition or that interpret the Nareit definition differently than we do. The GAAP measure that we believe to be most directly comparable to FFO, net income, includes depreciation and amortization expenses, gains or losses on property sales, impairments, and noncontrolling interests. In computing FFO, we eliminate these items because, in our view, they are not indicative of the results from the operations of our properties. To facilitate a clear understanding of our historical operating results, FFO should be examined in conjunction with net income (determined in accordance with GAAP) as presented in our financial statements. FFO does not represent cash generated from operating activities in accordance with GAAP, should not be considered to be an alternative to net income or loss (determined in accordance with GAAP) as a measure of our liquidity and is not indicative of funds available for our cash needs, including our ability to make cash distributions to shareholders.

~~Table of Contents~~

We use Normalized FFO, which excludes from FFO net change in fair value of derivative financial instruments, acceleration of deferred financing costs, net change in fair value of contingent consideration, gain on extinguishment of debt, and other normalizing items. Our Normalized FFO computation includes our share of required adjustments from our unconsolidated joint ventures and our use of the term Normalized FFO may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount. Normalized FFO should not be considered as an alternative to net income or loss (computed in accordance with GAAP), as an indicator of our financial performance or of cash flow from operating activities (computed in accordance with GAAP), or as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to make distributions. Normalized FFO should be reviewed in connection with other GAAP measurements.

Table of Contents

The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to FFO and Normalized FFO (in thousands, except per share data):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Net income	Net income	$	66,280	$	22,045	$	98,155	$	58,531	Net income	$	12,891	$	66,280	$	36,645	$	98,155
Earnings per share - diluted	Earnings per share - diluted	$	0.28	$	0.10	$	0.41	$	0.26	Earnings per share - diluted	$	0.05	$	0.28	$	0.15	$	0.41

Net income	Net income	$	66,280	$	22,045	$	98,155	$	58,531	Net income	$	12,891	$	66,280	$	36,645	$	98,155
Net income attributable to noncontrolling interests - partially owned properties	Net income attributable to noncontrolling interests - partially owned properties	(70)		(152)		(384)		(455)		Net income attributable to noncontrolling interests - partially owned properties	(51)		(70)		(121)		(384)
Preferred distributions		—		—		—		(13)

Depreciation and amortization expense	Depreciation and amortization expense	46,939		38,463		141,677		114,340		Depreciation and amortization expense	47,843		46,939		143,237		141,677
Depreciation and amortization expense - partially owned properties	Depreciation and amortization expense - partially owned properties	(101)		(70)		(241)		(210)		Depreciation and amortization expense - partially owned properties	(132)		(101)		(410)		(241)
Gain on sale of investment properties, net	Gain on sale of investment properties, net	(53,894)		(4,757)		(57,375)		(5,111)		Gain on sale of investment properties, net	—		(53,894)		(13)		(57,375)
Impairment loss		—		340		—		340

Proportionate share of unconsolidated joint venture adjustments	Proportionate share of unconsolidated joint venture adjustments	2,298		2,226		7,031		6,564		Proportionate share of unconsolidated joint venture adjustments	2,271		2,298		4,999		7,031
FFO applicable to common shares	FFO applicable to common shares	$	61,452	$	58,095	$	188,863	$	173,986	FFO applicable to common shares	$	62,822	$	61,452	$	184,337	$	188,863
Net change in fair value of derivative										Net change in fair value of derivative	185		—		185		—

Gain on extinguishment of debt										Gain on extinguishment of debt	(1,763)		—		(1,763)		—

Proportionate share of unconsolidated joint venture adjustments	Proportionate share of unconsolidated joint venture adjustments	(82)		—		(360)		—		Proportionate share of unconsolidated joint venture adjustments	—		(82)		—		(360)
Normalized FFO applicable to common shares	Normalized FFO applicable to common shares	$	61,370	$	58,095	$	188,503	$	173,986	Normalized FFO applicable to common shares	$	61,244	$	61,370	$	182,759	$	188,503

FFO per common share - diluted	FFO per common share - diluted	$	0.26	$	0.26	$	0.79	$	0.79	FFO per common share - diluted	$	0.25	$	0.26	$	0.74	$	0.79
Normalized FFO per common share - diluted	Normalized FFO per common share - diluted	$	0.26	$	0.26	$	0.79	$	0.79	Normalized FFO per common share - diluted	$	0.25	$	0.26	$	0.73	$	0.79

Weighted average common shares outstanding - diluted	Weighted average common shares outstanding - diluted	239,898,462		223,992,049		239,145,383		221,399,649		Weighted average common shares outstanding - diluted	249,445,312		239,898,462		249,226,913		239,145,383

Normalized ~~Funds Available for Distribution (FAD)~~FAD

We define Normalized FAD, a non-GAAP measure, which excludes from Normalized FFO non-cash share compensation expense, straight-line rent adjustments, amortization of acquired above-market or below-market leases and assumed debt, amortization of lease inducements, amortization of deferred financing costs, and loan reserve adjustments, including our share of all required adjustments from unconsolidated joint ventures. We also adjust for recurring capital expenditures related to building, site, and tenant improvements, ~~and~~ leasing commissions, ~~and~~ cash payments from seller master leases, and rent abatement payments, including our share of all required adjustments for unconsolidated joint ventures. Other REITs or real estate companies may use different methodologies for calculating Normalized FAD, and accordingly, our computation may not be comparable to those reported by other REITs. Although our computation of Normalized FAD may not be comparable to that of other REITs, we believe Normalized FAD provides a meaningful supplemental measure of our performance due to its frequency of use by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. Normalized FAD should not be considered as an alternative to net income or loss attributable to controlling interest (computed in

~~Table of Contents~~

accordance with GAAP) or as an indicator of our financial performance. Normalized FAD should be reviewed in connection with other GAAP measurements.

Table of Contents

The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to Normalized FAD (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Net income	Net income	$	66,280	$	22,045	$	98,155	$	58,531	Net income	$	12,891	$	66,280	$	36,645	$	98,155
Normalized FFO applicable to common shares	Normalized FFO applicable to common shares	$	61,370	$	58,095	$	188,503	$	173,986	Normalized FFO applicable to common shares	$	61,244	$	61,370	$	182,759	$	188,503

Normalized FFO applicable to common shares	Normalized FFO applicable to common shares	$	61,370	$	58,095	$	188,503	$	173,986	Normalized FFO applicable to common shares	$	61,244	$	61,370	$	182,759	$	188,503
Non-cash share compensation expense	Non-cash share compensation expense	4,349		3,665		12,400		10,840		Non-cash share compensation expense	3,968		4,349		12,290		12,400
Straight-line rent adjustments	Straight-line rent adjustments	(1,478)		(2,171)		(5,359)		(7,276)		Straight-line rent adjustments	(820)		(1,478)		(2,756)		(5,359)
Amortization of acquired above/below-market leases/assumed debt	Amortization of acquired above/below-market leases/assumed debt	1,133		833		3,773		2,557		Amortization of acquired above/below-market leases/assumed debt	1,084		1,133		3,338		3,773
Amortization of lease inducements	Amortization of lease inducements	225		394		675		922		Amortization of lease inducements	246		225		717		675
Amortization of deferred financing costs	Amortization of deferred financing costs	581		581		1,739		1,744		Amortization of deferred financing costs	763		581		2,028		1,739
TI/LC and recurring capital expenditures		(4,129)		(6,673)		(16,660)		(17,984)
Recurring capital expenditures and lease commissions										Recurring capital expenditures and lease commissions	(5,745)		(4,129)		(17,321)		(16,660)
Loan reserve adjustments	Loan reserve adjustments	152		20		159		(111)		Loan reserve adjustments	265		152		275		159

Proportionate share of unconsolidated joint venture adjustments	Proportionate share of unconsolidated joint venture adjustments	(403)		(153)		(900)		(578)		Proportionate share of unconsolidated joint venture adjustments	(939)		(403)		(1,384)		(900)
Normalized FAD applicable to common shares	Normalized FAD applicable to common shares	$	61,800	$	54,591	$	184,330	$	164,100	Normalized FAD applicable to common shares	$	60,066	$	61,800	$	179,946	$	184,330

~~Net Operating Income (NOI),~~NOI, Cash NOI, and ~~MOB~~Outpatient Medical Same-Store Cash NOI

NOI is a non-GAAP financial measure that is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties and other investments before general and administrative expenses, depreciation and amortization expense, interest expense, corporate high yield interest income, swap income, net change in the fair value of derivative financial instruments, gain or loss on the sale of investment properties, and impairment losses, including our share of all required adjustments from our unconsolidated joint ventures. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. Our use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.

Cash NOI is a non-GAAP financial measure which excludes from NOI straight-line rent adjustments, amortization of acquired above and below market leases, and other non-cash and normalizing items, including our share of all required adjustments from unconsolidated joint ventures. Other non-cash and normalizing items include items such as the amortization of lease inducements, loan reserve adjustments, payments received from seller master leases and rent abatements, and changes in fair value of contingent consideration. We believe that Cash NOI provides an accurate measure of the operating performance of our operating assets because it excludes certain items that are not associated with management of the properties. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance in the real estate community. Our use of the term Cash NOI may not be comparable to that of other real estate companies as such other companies may have different methodologies for computing this amount.

~~MOB~~Outpatient Medical Same-Store Cash NOI is a non-GAAP financial measure which excludes from Cash NOI assets not held for the entire preceding five quarters, ~~non-MOB~~non-outpatient medical facility assets, and other normalizing items not specifically related to the same-store property portfolio. Management considers ~~MOB~~Outpatient Medical Same-Store Cash NOI a supplemental measure because it allows investors, analysts, and Company management to measure unlevered property-level operating results. Our use of the term ~~MOB~~Outpatient Medical Same-Store Cash NOI may not be comparable to that of other real estate companies, as such other companies may have different methodologies for computing this amount.

3133

Table of Contents

The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to NOI, Cash NOI, and ~~MOB~~Outpatient Medical Same-Store Cash NOI (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Net income	Net income	$	66,280	$	22,045	$	98,155	$	58,531	Net income	$	12,891	$	66,280	$	36,645	$	98,155
General and administrative	General and administrative	10,079		9,534		30,400		28,116		General and administrative	9,771		10,079		31,133		30,400

Depreciation and amortization expense	Depreciation and amortization expense	47,040		38,582		142,002		114,663		Depreciation and amortization expense	47,932		47,040		143,555		142,002
Interest expense	Interest expense	18,299		13,498		52,356		40,754		Interest expense	20,050		18,299		59,837		52,356
Corporate high yield interest income										Corporate high yield interest income	(2,307)		—		(3,284)		—
Swap income										Swap income	(244)		—		(244)		—
Net change in the fair value of derivative										Net change in the fair value of derivative	185		—		185		—
Gain on sale of investment properties, net										Gain on sale of investment properties, net	—		(53,894)		(13)		(57,375)

Gain on sale of investment properties, net		(53,894)		(4,757)		(57,375)		(5,111)
Impairment loss		—		340		—		340
Proportionate share of unconsolidated joint venture adjustments	Proportionate share of unconsolidated joint venture adjustments	3,463		3,653		10,289		10,725		Proportionate share of unconsolidated joint venture adjustments	3,542		3,463		8,944		10,289
NOI	NOI	$	91,267	$	82,895	$	275,827	$	248,018	NOI	$	91,820	$	91,267	$	276,758	$	275,827

NOI	NOI	$	91,267	$	82,895	$	275,827	$	248,018	NOI	$	91,820	$	91,267	$	276,758	$	275,827
Straight-line rent adjustments	Straight-line rent adjustments	(1,478)		(2,171)		(5,359)		(7,276)		Straight-line rent adjustments	(820)		(1,478)		(2,756)		(5,359)
Amortization of acquired above/below-market leases	Amortization of acquired above/below-market leases	1,133		849		3,783		2,604		Amortization of acquired above/below-market leases	1,084		1,133		3,338		3,783
Amortization of lease inducements	Amortization of lease inducements	225		394		675		922		Amortization of lease inducements	246		225		717		675
Loan reserve adjustments	Loan reserve adjustments	152		20		159		(111)		Loan reserve adjustments	265		152		275		159

Proportionate share of unconsolidated joint venture adjustments	Proportionate share of unconsolidated joint venture adjustments	(176)		(143)		(346)		(459)		Proportionate share of unconsolidated joint venture adjustments	(101)		(176)		(293)		(346)
Cash NOI	Cash NOI	$	91,123	$	81,844	$	274,739	$	243,698	Cash NOI	$	92,494	$	91,123	$	278,039	$	274,739

Cash NOI	Cash NOI	$	91,123	$	81,844					Cash NOI	$	92,494	$	91,123
Assets not held for all periods or held for sale		(12,785)		(3,304)
Hospital Cash NOI		(2,775)		(2,519)
Assets not held for all periods										Assets not held for all periods	(1,516)		(478)

Non-outpatient medical facilities										Non-outpatient medical facilities	(2,816)		(2,775)
Lease termination fees	Lease termination fees	—		(158)						Lease termination fees	—		13
Interest income on real estate loans	Interest income on real estate loans	(2,517)		(3,797)						Interest income on real estate loans	(1,572)		(2,517)
Joint venture and other income	Joint venture and other income	(3,595)		(3,350)						Joint venture and other income	(3,581)		(3,618)
MOB Same-Store Cash NOI		$	69,451	$	68,716
Outpatient Medical Same-Store Cash NOI										Outpatient Medical Same-Store Cash NOI	$	83,009	$	81,748

~~Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre)~~EBITDAre and Adjusted EBITDAre

We calculate EBITDAre in accordance with standards established by Nareit and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, corporate high yield interest income, swap income, gain or loss on the sale of investment properties, and impairment loss, including our share of all required adjustments from unconsolidated joint ventures. We define Adjusted EBITDAre, which excludes from EBITDAre non-cash share compensation expense, non-cash changes in fair value, pursuit costs, non-cash intangible amortization, corporate high yield interest income, the pro forma impact of investment activity, and other normalizing items. We consider EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

3234

Table of Contents

The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to EBITDAre and Adjusted EBITDAre (in thousands):


		Three Months Ended September 30,					Three Months Ended September 30,
		2022		2021			2023		2022
Net income	Net income	$	66,280	$	22,045	Net income	$	12,891	$	66,280
Depreciation and amortization expense	Depreciation and amortization expense	47,040		38,582		Depreciation and amortization expense	47,932		47,040
Interest expense	Interest expense	18,299		13,498		Interest expense	20,050		18,299
Corporate high yield interest income						Corporate high yield interest income	(2,307)		—
Swap income						Swap income	(244)		—
Gain on sale of investment properties, net	Gain on sale of investment properties, net	(53,894)		(4,757)		Gain on sale of investment properties, net	—		(53,894)
Impairment loss		—		340

Proportionate share of unconsolidated joint venture adjustments	Proportionate share of unconsolidated joint venture adjustments	3,545		3,627		Proportionate share of unconsolidated joint venture adjustments	3,526		3,545
EBITDAre	EBITDAre	$	81,270	$	73,335	EBITDAre	$	81,848	$	81,270

Non-cash share compensation expense	Non-cash share compensation expense	4,349		3,665		Non-cash share compensation expense	3,968		4,349

Non-cash changes in fair value						Non-cash changes in fair value	185		—
Pursuit costs	Pursuit costs	149		75		Pursuit costs	241		149
Non-cash intangible amortization	Non-cash intangible amortization	1,358		1,227		Non-cash intangible amortization	1,330		1,358
Proportionate share of unconsolidated joint venture adjustments	Proportionate share of unconsolidated joint venture adjustments	(82)		—		Proportionate share of unconsolidated joint venture adjustments	—		(82)
Pro forma adjustments for investment activity	Pro forma adjustments for investment activity	871		585		Pro forma adjustments for investment activity	45		871
Adjusted EBITDAre	Adjusted EBITDAre	$	87,915	$	78,887	Adjusted EBITDAre	$	87,617	$	87,915

Liquidity and Capital Resources

In March 2020, the Securities and Exchange Commission (SEC) adopted amendments to Rule 3-10 of Regulation S-X and created Rule 13-01 to simplify disclosure requirements related to certain registered securities. The rule is effective January 4, 2021 but earlier compliance is permitted. As a result of the amendments to Rule 3-10 of Regulation S-X, subsidiary issuers of obligations guaranteed by the parent are not required to provide separate financial statements, provided that the subsidiary obligor is consolidated into the parent company’s consolidated financial statements, the parent guarantee is “full and unconditional” and the alternative disclosure required by Rule 13-01 is provided, which includes narrative disclosure and summarized financial information. Accordingly, separate consolidated financial statements of the Operating Partnership have not been presented. Furthermore, as permitted under Rule 13-01(a)(4)(vi), the Company has excluded the summarized financial information for the Operating Partnership as the assets, liabilities, and results of operations of the Company and the Operating Partnership are not materially different than the corresponding amounts presented in the consolidated financial statements of the Company, and management believes such summarized financial information would be repetitive and not provide incremental value to investors.

Our short-term liquidity requirements consist primarily of operating and interest expenses and other expenditures directly associated with our properties, including:

•property expenses;

•interest expense and scheduled principal payments on outstanding indebtedness;

•general and administrative expenses; and

•capital expenditures for tenant improvements and leasing commissions.

In addition, we will require funds for future distributions expected to be paid to our common shareholders and OP Unit holders in our Operating Partnership.

As of September 30, ~~2022,~~2023, we had a total of ~~$2.5~~$195.8 million of cash and cash equivalents and ~~$738.0 million~~$1.0 billion of near-term availability on our unsecured revolving credit facility. Our primary sources of cash include rent we collect from our tenants, borrowings under our unsecured credit facility, and ~~financings~~financing of debt and equity securities. We believe that our existing cash and cash equivalents, cash flow from operating activities, and borrowings available under our unsecured revolving credit facility will be adequate to fund any existing contractual obligations to purchase properties and other obligations through the next year. However, because of the 90% distribution requirement under the REIT tax rules under the Internal Revenue Code, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely upon external sources of capital, including debt and equity financing, to fund future capital needs. If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature.

~~Table of Contents~~

We will rely upon external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.

Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, recurring and non-recurring capital expenditures, and scheduled debt maturities. We expect to satisfy our long-term liquidity needs through cash flow from operations, unsecured borrowings, issuances of equity and debt securities, proceeds from select property dispositions and joint venture transactions, and, in connection with acquisitions of additional properties, the issuance of OP Units of our Operating Partnership.

Table of Contents

Our ability to access capital in a timely and cost-effective manner is essential to the success of our business strategy as it affects our ability to satisfy existing obligations, including repayment of maturing indebtedness, and to make future investments and acquisitions. Factors such as general market conditions, interest rates, credit ratings on our debt and equity securities, expectations of our potential future earnings and cash distributions, and the market price of our common shares, each of which are beyond our control and vary or fluctuate over time, all impact our access to and cost of capital. In particular, to the extent interest rates continue to rise, we may continue to experience a decline in the trading price of our common shares, which may impact our decision to conduct equity offerings for capital raising purposes. We have experienced and will likely ~~also~~continue to experience higher borrowing costs as interest rates rise, which may also impact our decisions to incur additional indebtedness, or to engage in transactions ~~for which~~that we may need to fund through borrowing. We expect to continue to utilize equity and debt ~~financings~~financing to support our future growth and investment activity.

We also continuously evaluate opportunities to finance future investments. New investments are generally funded from temporary borrowings under our primary unsecured credit facility and the proceeds from financing transactions such as those discussed above. Our investments generate cash from net operating income and principal payments on loans receivable. Permanent financing for future investments, which generally replaces funds drawn under our primary unsecured credit facility, has historically been provided through a combination of the issuance of debt and equity securities and the incurrence or assumption of secured debt.

We intend to invest in additional properties as suitable opportunities arise and adequate sources of financing are available. We are currently evaluating additional potential investments consistent with the normal course of our business. There can be no assurance as to whether or when any portion of these investments will be completed. Our ability to complete investments is subject to a number of risks and variables, including our ability to negotiate mutually agreeable terms with sellers and our ability to finance the investment. We may not be successful in identifying and consummating suitable acquisitions or investment opportunities, which may impede our growth and negatively affect our results of operations and may result in the use of a significant amount of management’s resources. We expect that future investments in properties will depend on and will be financed by, in whole or in part, our existing cash, borrowings, including under our unsecured revolving credit facility, or the proceeds from additional issuances of equity or debt securities.

We currently do not expect to sell any of our properties to meet our liquidity needs, although we may do so in the future.

We currently are in compliance with all debt covenants on our outstanding indebtedness.

The foregoing discussion regarding the Company’s liquidity and capital resources is subject to applicable restrictions in the Merger Agreement.

Credit Facility

On September 24, 2021, the Operating Partnership, as borrower, and the Trust, as guarantor, executed the Credit Agreement which extended the maturity date of the revolving credit facility under the Credit Agreement to September 24, 2025 and reduced the interest rate margin applicable to borrowings. The Credit Agreement includes an unsecured revolving credit facility of $1.0 billion and contains a term loan feature of ~~$250~~$250.0 million, which the Company borrowed on, bringing total borrowing capacity to ~~$1.3~~$1.25 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Trust to increase borrowing capacity by up to an additional $500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.75 billion. On October 13, 2021, the Company paid off the $250.0 million term loan feature of the Credit Agreement and the term loan feature is no longer available to the Company. The revolving credit facility under the Credit Agreement also includes two six-month extension options.

On ~~October 13, 2021,~~March 31, 2023, the ~~Company used the proceeds from the 2031 Senior Notes to pay off a $250.0 million term loan feature of the Credit Agreement. The~~ Operating Partnership, ~~simultaneously terminated~~as borrower, and the ~~existing pay-fixed receive-variable rate swaps associated with the full term loan borrowing of $250.0 million. As part of the termination, the Company made total cash payments of $3.3 million~~Trust, as guarantor, executed a First Amendment to ~~the counterparties of the swap agreements. As defined by~~ the Credit Agreement which expanded the ~~term loan~~accordion feature ~~is no longer available~~allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, resulting in a maximum borrowing capacity of $2.25 billion, and replaced the ~~Company.~~LIBOR-based benchmark rates applicable to borrowings under the Amended Credit Agreement with SOFR based benchmark rates.

Table of Contents

principal amount of all revolving commitments and term loans under the Credit Agreement of $1.9 billion. On the same day, the Operating Partnership borrowed $400.0 million under the five-year term loan feature of the Credit Agreement. Borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust’s credit rating, currently equal to 1.10%, inclusive of a 0.10% SOFR index adjustment, plus Daily Simple SOFR. The Company simultaneously entered into fixed-for-floating interest rate swaps for the full borrowing amount under the term loan, fixing the Daily Simple SOFR (as defined in the Credit Agreement) component of the borrowing rate to 3.593%, for an all-in fixed rate of 4.693%. Both the borrowing and the fixed-for-floating rate swaps have a maturity date of May 24, 2028. A portion of the proceeds from the term loan were used to repay all amounts outstanding on the unsecured revolving credit facility.

As of September 30, ~~2022,~~2023, the Company did not have any borrowings outstanding under its $1.0 billion unsecured revolving credit facility or the $500.0 million accordion feature, as defined by the Credit Agreement. Of the aggregate $1.9 billion available under the Credit Agreement, the Company had ~~$262.0~~$400.0 million of borrowings outstanding under ~~its unsecured revolving credit facility. As defined by~~ the ~~Credit Agreement, $738.0 million is available to borrow without adding additional properties to the unencumbered borrowing base~~term loan feature as of ~~assets.~~September 30, 2023. See Note 6 (Debt) to our accompanying consolidated financial statements for a further discussion of our credit facility.

Senior Notes

As of September 30, ~~2022,~~2023, we had $1.5 billion aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, comprised of ~~$15.0 million maturing in 2023,~~ $25.0 million maturing in 2025, $70.0 million maturing in 2026, $425.0 million maturing in 2027, $395.0 million maturing in 2028, and $545.0 million maturing in 2031. See Note 6 (Debt) to our accompanying consolidated financial statements for a further discussion of our senior notes.

ATM Program

In May 2021, the Company entered into the 2021 Sales Agreement, pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $500 million. In accordance with the 2021 Sales Agreement, the Trust may offer and sell its common shares through the 2021 Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, which includes sales made directly on the New York Stock Exchange or other existing trading market, or sales made to or through a market maker.

In August 2023, the Company entered into the 2023 Sales Agreement, pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $600 million. In accordance with the 2023 Sales Agreement, the Trust may offer and sell its common shares through the 2023 Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the New York Stock Exchange or other existing trading market, or sales made to or through a market maker.

~~During~~ Upon entry into the ~~quarters ended March 31, 2022, June 30, 2022, and September 30, 2022,~~2023 Sales Agreement, the ~~Trust issued and sold common shares through~~Company terminated the 2021 ATM ~~Program as follows (net proceeds in thousands):~~

Program. As of September 30, ~~2022,~~2023, the Trust has ~~$300.1~~$600.0 million ~~of common shares~~ remaining available under the 2023 ATM Program. Subsequent to September 30, 2023, in connection with the Merger Agreement, the Trust suspended the 2023 ATM Program.

Dividend Reinvestment and Share Purchase Plan

In December 2014, the Company adopted a Dividend Reinvestment and Share Purchase Plan (“DRIP”). Under the DRIP:

•existing shareholders may purchase additional common shares by reinvesting all or a portion of the dividends paid on their common shares and by making optional cash payments of not less than $50 and up to a maximum of $10,000 per month;

•new investors may join the DRIP by making an initial investment of not less than $1,000 and up to a maximum of $10,000; and

•once enrolled in the DRIP, participants may authorize electronic deductions from their bank account for optional cash payments to purchase additional shares.

The DRIP is administered by our transfer agent, Computershare Trust Company, N.A. Our common shares sold under the DRIP are newly issued or purchased in the open market, as further described in the DRIP. As of September 30, ~~2022,~~2023, the Company had issued ~~202,460~~231,183 common shares under the DRIP since its inception.

3537

Table of Contents

Critical Accounting Policies

Our consolidated financial statements included in Part I, Item 1 of this report are prepared in conformity with GAAP for interim financial information set forth in the ASC, as published by the ~~Financial Accounting Standards Board,~~FASB, which require us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions, and in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to our ~~2021~~2022 Annual Report for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our consolidated financial statements included in Part I, Item 1 of this report.

REIT Qualification Requirements

We are subject to a number of operational and organizational requirements necessary to qualify and maintain our qualification as a REIT. If we fail to qualify as a REIT or fail to remain qualified as a REIT in any taxable year, our income would be subject to federal income tax at regular corporate rates and potentially increased state and local taxes and we could incur substantial tax liabilities which could have an adverse impact upon our results of operations, liquidity, and distributions to our shareholders.

Off-Balance Sheet Arrangements

As of September 30, ~~2022,~~2023, we have investments in two unconsolidated joint ventures with ownership interests of ~~49.0%~~46.5% and 12.3%, respectively. The aggregate carrying amount of debt, including both our and our partners’ share, incurred by these ventures was approximately ~~$795.4~~$766.2 million (of which our proportionate share is approximately ~~$144.2~~$141.5 million). See Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our ~~2021~~2022 Annual Report for the fiscal year ended December 31, ~~2021~~2022 for additional information. We have no other off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our future income, cash flows, and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We do not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. Our derivative instruments consist of ~~one~~four interest rate ~~swap.~~swaps of which three are designated as cash flow hedges of interest rate risk. See Note 7 (Derivatives) ~~in Part I, Item I of this report~~ and Note 2 (Summary of Significant Accounting Policies) in Part I, Item 1 of ~~Part II, Item 8 (Financial Statements and Supplementary Data) of our 2021 Annual Report~~this report for further detail on our interest rate ~~swap.~~swaps.

Interest rate risk amounts are our management’s estimates and were determined by considering the effect of hypothetical interest rates on our consolidated financial instruments. These analyses do not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of that magnitude, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, these analyses assume no changes in our financial structure.

Fixed Interest Rate Debt

As of September 30, ~~2022,~~2023, our consolidated fixed interest rate debt totaled $1.5 billion, which represented ~~78.8%~~74.6% of our total consolidated debt, excluding the impact of ~~the~~ interest rate ~~swap.~~swaps. We entered into ~~a pay-fixed receive-variable~~fixed-for-floating interest rate ~~swap~~swaps for ~~$36.1 million~~the full borrowing amount of our ~~mortgage debt,~~$400.0 million term loan, fixing the ~~LIBOR~~Daily Simple SOFR (as defined in the Credit Agreement) component of the borrowing rate to ~~1.43%~~3.593%, for an all-in fixed rate as of September 30, ~~2022~~2023 of ~~3.33%~~4.693%. Both the borrowing and ~~pay-fixed receive-variable swap~~the fixed-for-floating rate swaps have a maturity date of ~~October 31, 2024.~~May 24, 2028.

Assuming the effects of our interest rate swap ~~agreement,~~agreements, our fixed interest rate debt would represent ~~80.7%~~94.7% of our total consolidated debt. Interest rate fluctuations on our fixed interest rate debt will generally not affect our future earnings or

3638

Table of Contents

cash flows unless such instruments mature or are otherwise terminated. However, interest rate changes could affect the fair value of our fixed interest rate debt.

As of September 30, ~~2022,~~2023, the fair value and the carrying value of our consolidated fixed interest rate debt were approximately $1.3 billion and $1.5 billion, respectively. The fair value estimate of our fixed interest rate debt was estimated using a discounted cash flow analysis utilizing rates we would expect to pay for debt of a similar type and remaining maturity if the loans were originated on September 30, ~~2022.~~2023. As we expect to hold our fixed interest rate debt instruments to maturity, based on the underlying structure of the debt instrument, and the amounts due under such instruments are limited to the outstanding principal balance and any accrued and unpaid interest, we do not expect that market fluctuations in interest rates, and the resulting change in fair value of our fixed interest rate debt instruments, would have a significant impact on our operating cash flows.

Variable Interest Rate Debt

As of September 30, ~~2022,~~2023, our consolidated variable interest rate debt totaled ~~$403.3~~$504.8 million, which represented ~~21.2%~~25.4% of our total consolidated debt. Assuming the effects of our interest rate swap ~~agreement,~~agreements, our variable interest rate debt would represent ~~19.3%~~5.3% of our total consolidated debt. Interest rate changes on our variable rate debt could impact our future earnings and cash flows but would not significantly affect the fair value of such debt. As of September 30, ~~2022,~~2023, we were exposed to market risks related to fluctuations in interest rates on ~~$367.3~~$104.8 million of consolidated borrowings. Assuming no increase in the amount of our variable rate debt, if ~~LIBOR~~PRIME and SOFR were to change by 100 basis points, total interest expense on our variable rate debt as of September 30, ~~2022~~2023 would change by approximately ~~$2.7 million and~~ $1.0 million ~~annually, respectively.~~annually.

Derivative Instruments

As of September 30, ~~2022,~~2023, we had ~~one~~four outstanding interest rate ~~swap that was~~swaps of which three are designated as a cash flow ~~hedge~~hedges of interest rate risk, with a total notional amount of ~~$36.1~~$436.1 million. See Note 7 (Derivatives) within our consolidated financial statements for further detail on our interest rate ~~swap.~~swaps. We are exposed to credit risk of the counterparty to our interest rate swap ~~agreement~~agreements in the event of non-performance under the terms of the agreements. If we were not able to replace the ~~swap~~swaps in the event of non-performance by the counterparty, we would be subject to variability of the interest rate on the amount outstanding under our debt that is fixed through the use of the swap.

Indebtedness

As of September 30, ~~2022,~~2023, we had total consolidated indebtedness of approximately ~~$1.9~~$2.0 billion. The weighted average interest rate on our consolidated indebtedness was ~~3.75%~~4.07% (based on the 30-day ~~LIBOR rate of 2.92% and a~~ SOFR rate of ~~2.98%~~5.31% and a PRIME rate of 8.50% as of September 30, ~~2022)~~2023). As of September 30, ~~2022,~~2023, we had approximately ~~$367.3~~$104.8 million, or approximately ~~19.3%~~5.3%, of our outstanding long-term debt exposed to fluctuations in short-term interest rates. See Note 6 (Debt) to our consolidated financial statements included in Part I, Item 1 to this report for a summary of our indebtedness as of September 30, ~~2022.~~2023.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Trust’s management, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Trust’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on such evaluation, the Trust’s Chief Executive Officer and Chief Financial Officer concluded that as of September 30, ~~2022,~~2023, the Trust’s disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Trust’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

~~Table of Contents~~

Changes in Internal Control over Financial Reporting

There have been no changes in the Trust’s system of internal control over financial reporting during the quarter ended September 30, ~~2022~~2023 that have materially affected, or are reasonably likely to materially affect, the Trust’s internal control over financial reporting.

Table of Contents

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and the Trust’s internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Trust’s internal control over financial reporting must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

3840

Table of Contents

PART II. Other Information

Item 1. Legal Proceedings

From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition, or results of operations if determined adversely to us.

Item 1A. Risk Factors

Information on risk factors can be found in Part I, Item 1A (Risk Factors) of our ~~2021~~2022 Annual Report. There have been no material changes from the risk factors previously disclosed in our ~~2021~~2022 Annual ~~Report.~~Report, other than risks related to the Mergers and the Merger Agreement set forth below.

Risks Related to the Mergers

The Exchange Ratio is fixed and will not be adjusted in the event of any change in the stock prices of either Healthpeak or the Trust.

Upon the closing of the Company Merger, each outstanding common share of the Trust (other than common shares to be canceled in accordance with the Merger Agreement) will be converted into the right to receive 0.674 shares of Healthpeak common stock, without interest, but subject to any withholding required under applicable tax law, with cash paid in lieu of any fractional shares. The Exchange Ratio was fixed in the Merger Agreement and, except for certain adjustments on account of changes in the capitalization of Healthpeak or the Trust, will not be adjusted for changes in the market prices of shares of Healthpeak common stock or the Trust common shares. Changes in the market price of shares of Healthpeak common stock prior to the closing of the Company Merger will affect the market value of the Merger Consideration that the Trust shareholders will be entitled to receive upon completion of the Company Merger. Stock price changes may result from a variety of factors (many of which are beyond the control of either Healthpeak or the Trust), including the following factors:

•market reaction to the announcement of the Mergers and the prospects of the combined company;

•changes in the respective businesses, operations, assets, liabilities and prospects of Healthpeak, the Trust or the combined company;

•changes in market assessments of the business, operations, financial position and prospects of Healthpeak, the Trust or the combined company;

•market assessments of the likelihood that the Mergers will close;

•interest rates (including changes or anticipated changes in interest rates), general market and economic conditions and other factors generally affecting the market prices of Healthpeak common stock and the Trust common shares;

•federal, state and local legislation, governmental regulation and legal developments in the businesses in which Healthpeak or the Trust operate; and

•other factors beyond the control of either Healthpeak or the Trust, including those described or referred to elsewhere in this “Risk Factors” section.

The market price of shares of Healthpeak common stock at the closing of the Mergers may vary from its price on the date the Merger Agreement was executed, on the date of the joint proxy statement/prospectus, on the date of the Healthpeak special meeting and on the date of the Trust special meeting.

If the market price of shares of Healthpeak common stock increases between the date the Merger Agreement was signed, the date of the joint proxy statement/prospectus, the date of the Healthpeak special meeting or the date of the Trust special meeting and the date of the closing of the Mergers, the Trust shareholders could receive shares of Healthpeak common stock that have a market value upon completion of the Mergers that is greater than the market value of such shares calculated pursuant to the Exchange Ratio on the date the Merger Agreement was signed, the date of the joint proxy statement/prospectus, the date of the Healthpeak special meeting or the date of the Trust special meeting, respectively. Conversely, if the market price of shares of Healthpeak common stock declines between the date the Merger Agreement was signed, the date of the joint proxy statement/prospectus, the date of the Healthpeak special meeting or the date of the Trust special meeting and the closing of the Mergers, the Trust shareholders could receive shares of Healthpeak common stock that have a market value upon the closing of the Mergers that is less than the market value of such shares calculated pursuant to the Exchange Ratio on the date the Merger Agreement was signed, the date of the joint proxy statement/prospectus, the date of the Healthpeak special meeting or the date of the Trust special meeting, respectively. Furthermore, at the time of the Healthpeak special meeting and the Trust special meeting, Healthpeak stockholders and the Trust shareholders will not know with certainty the value of the Healthpeak common stock that the Trust shareholders will receive upon completion of the Mergers.

Table of Contents

Therefore, while the number of shares of Healthpeak common stock to be issued per the Trust common share is fixed, Healthpeak stockholders and the Trust shareholders cannot be sure of the market value of the Merger Consideration the Trust shareholders will receive upon the closing of the Mergers.

Completion of the Mergers is subject to many conditions, and if these conditions are not satisfied or waived, the Mergers will not be completed, which could result in a requirement that the Trust pay certain termination fees.

The consummation of the Mergers is subject to certain conditions, including (i) the receipt of approval from the Trust’s shareholders; (ii) the receipt of approval from Healthpeak’s stockholders; (iii) the effectiveness of the registration statement on Form S-4 to be filed with the Commission by the parties in connection with the transactions contemplated by the Merger Agreement; (iv) approval for listing on the New York Stock Exchange of the shares of Healthpeak Common Stock to be issued in the Mergers or reserved for issuance in connection therewith; (v) no temporary restraining order, preliminary or permanent injunction or other order, decree or judgment being in effect enjoining, preventing, restraining, making illegal or otherwise prohibiting the consummation of the Mergers; (vi) no law having been enacted, issued, entered, promulgated or enforced by any governmental authority being in effect which would have the effect of enjoining, preventing, restraining, making illegal or otherwise prohibiting the consummation of the Mergers; (vii) accuracy of each party’s representations, subject in most cases to materiality or Material Adverse Effect (as defined in the Merger Agreement) qualifications; (viii) material compliance with each party’s covenants; (ix) absence of a Material Adverse Effect on either Healthpeak or the Trust; (x) receipt by each of Healthpeak and the Trust of an opinion to the effect that the Company Merger will qualify as a “reorganization” within the meaning of Section 368(a) of the Internal Revenue Code and (xi) receipt by Healthpeak of an opinion that the Trust qualifies as a REIT under the Code and receipt by the Trust of an opinion that Healthpeak qualifies as a REIT under the Internal Revenue Code.

There can be no assurance that the conditions to the closing of the Mergers will be satisfied or waived or that the Mergers will be completed. Failure to consummate the Mergers may adversely affect the Company’s results of operations and business prospects for the following reasons, among others: (i) the Company has incurred and will incur certain transaction costs, regardless of whether the proposed Mergers close, which could adversely affect our financial condition, results of operations and ability to make distributions to our shareholders; and (ii) the proposed Mergers, whether or not they close, will divert the attention of certain of the Company’s management and other key employees from ongoing business activities, including the pursuit of other opportunities that could be beneficial to the Company. In addition, the Trust or Healthpeak may terminate the Merger Agreement under certain circumstances, including, among other reasons, if the Mergers are not completed by July 31, 2024.

If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement, the Trust may be required to pay Healthpeak a termination fee of $111 million, or the maximum amount that can be paid to Healthpeak without causing it to fail to meet its REIT requirement for such year, and/or reimburse Healthpeak’s transaction expenses up to an amount equal to $20 million, or Healthpeak may be required to pay the Trust a termination fee of $365 million, or the maximum amount that can be paid to Healthpeak without causing it to fail to meet its REIT requirement for such year, and/or reimburse the Trust’s transaction expenses up to an amount equal to $20 million. If the Mergers are not consummated, the price of the Trust common shares might decline.

Failure to complete the Mergers could negatively impact the stock prices and the future business and financial results of the Trust.

If the Mergers are not completed, the ongoing business of the Trust could be materially adversely affected and without realizing any of the benefits of having completed the Mergers, the Trust will be subject to a variety of risks associated with the failure to complete the Mergers, including the following:

•the market price of the Trust common shares could decline;

•the Trust being required, under certain circumstances, to pay to Healthpeak a termination fee of $111 million depending on the circumstances and/or reimburse Healthpeak’s reasonable expenses up to $20 million, as applicable;

•if the Merger Agreement is terminated and the Board of Trustees seeks another business combination, the Trust shareholders cannot be certain that the Trust will be able to find a party willing to enter into a transaction on terms equivalent to or more attractive than the terms that Healthpeak and the Trust have agreed to in the Merger Agreement;

•the Trust may experience negative reactions from the financial markets or its tenants, property managers or employees;

•the Trust having to pay certain costs relating to the Mergers, such as legal, accounting, financial advisor, filing, printing and mailing fees whether or not the Mergers are completed; and

•diversion of the Company’s management focus and resources from operational matters and other strategic opportunities while working to implement the Mergers.

Table of Contents

If the Mergers are not completed, these risks could materially affect the business, financial results and price of the common shares of the Trust. In addition, if the Mergers are not completed, the Trust could be subject to litigation related to any failure to complete the Mergers or related to any enforcement proceeding commenced against the Trust to perform its obligations under the Merger Agreement. The materialization of any of these risks could adversely impact the Company’s ongoing business.

The pendency of the Mergers could adversely affect the business and operations of the Company.

Prior to the effective time of the Mergers, some tenants, prospective tenants or property managers of the Company may delay or defer decisions, which could negatively affect the revenues, earnings, cash flows and expenses of the Company, regardless of whether the Mergers are completed. In addition, under our ground leases, certain hospitals or health systems could exercise purchase rights and rights of first offer and first refusal with respect to sales of the property subject to the ground lease. Similarly, current and prospective employees of the Company may experience uncertainty about their future roles with the combined company following the Mergers, which may materially adversely affect the ability of the Company to attract and retain key personnel during the pendency of the Mergers. Further, due to operating restrictions in the Merger Agreement, the Company may be unable, during the pendency of the Mergers, to pursue strategic transactions, undertake significant capital projects, undertake certain significant financing transactions and otherwise pursue other actions, even if such actions would prove beneficial.

The Merger Agreement contains provisions that could make it difficult for a third party to acquire all or a significant portion of the Trust prior to the Mergers.

Pursuant to the Merger Agreement, the Trust has agreed not to (i) solicit proposals relating to certain alternative transactions, (ii) engage in discussions or negotiations or provide non-public information in connection with any proposal for an alternative transaction from a third party or (iii) approve or enter into any agreements providing for any such alternative transaction, in each case, subject to certain exceptions, including to permit members of the Board of Trustees to comply with their duties under applicable law. Notwithstanding these “no-shop” restrictions, prior to obtaining the Trust shareholder approval, under specified circumstances the Board of Trustees may change its recommendation of the transaction, and the Trust may also terminate the Merger Agreement to accept a superior proposal upon payment of the termination fee described below.

The Merger Agreement provides that, in connection with the termination of the Merger Agreement under specified circumstances, the Trust may be required to pay to Healthpeak a termination fee of $111 million and/or reimburse Healthpeak’s transaction expenses up to an amount equal to $20 million. These provisions could discourage a potential competing acquirer that might have an interest in acquiring all or a significant part of the Trust from considering or proposing such an acquisition, even if the potential competing acquirer was prepared to pay consideration with a higher per share value than the value proposed to be received or realized in the Mergers, or might result in a potential competing acquirer proposing to pay a lower per share value than it might otherwise have proposed to pay because of the added expense of the termination fee that may become payable in certain circumstances under the Merger Agreement.

If the Merger Agreement is terminated and the Trust determines to seek another business combination, the Trust may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the Mergers contemplated by the Merger Agreement.

If the Mergers are not consummated by July 31, 2024, either Healthpeak or the Trust may terminate the Merger Agreement.

Either Healthpeak or the Trust may terminate the Merger Agreement if the Mergers have not been consummated by July 31, 2024. However, this termination right will not be available to a party whose material breach of any provision of the Merger Agreement was the primary cause of, or resulted in, the failure of the Mergers to occur on or before July 31, 2024.

If the Company Merger does not qualify as a reorganization, there may be adverse tax consequences.

The Company Merger is intended to qualify as a reorganization within the meaning of Section 368(a) of the Code. It is a condition to the completion of the Mergers that Healthpeak and the Trust receive written opinions from their respective counsel to the effect that the Company Merger will qualify as a reorganization within the meaning of Section 368(a) of the Code. The foregoing opinions, however, are limited to the factual representations provided by Healthpeak and the Trust to counsel and the assumptions set forth therein, and are not a guarantee that the Company Merger will, in fact, qualify as a reorganization. Furthermore, such opinions are not binding on the IRS. Neither the Trust nor Healthpeak has requested or plans to request a ruling from the IRS that the Company Merger qualifies as a reorganization. If the Company Merger were to fail to qualify as a reorganization, then each United States holder of the Trust common shares generally would recognize gain or loss, as applicable, equal to the difference between (i) the sum of the fair market value of the shares of Healthpeak common stock and cash in lieu of any fractional share of Healthpeak common stock received by such holder in the Company Merger; and (ii) such holder’s adjusted tax basis in its Trust common shares.

Table of Contents

An adverse outcome in any litigation or other legal proceedings relating to the Merger Agreement, or the transactions contemplated thereby, could have a material adverse impact on the business of the Company or its ability to consummate the transactions contemplated by the Merger Agreement.

Transactions like the Mergers are frequently the subject of litigation, shareholder demands, or other legal proceedings, including actions alleging that either party’s board of directors breached their respective duties to their shareholders or other equity holders by entering into the Merger Agreement, by failing to obtain a greater value in the transaction for their stockholders or other equity holders or otherwise, or any other claims (contractual or otherwise) arising out of the Mergers or the transactions related thereto. An adverse outcome in such matters, as well as the costs and efforts of a defense even if successful, could have a material adverse effect on the parties’ ability to consummate the Mergers in a timely manner, or at all, or their respective business, results of operation or financial position, including through the possible diversion of either company’s resources or distraction of key personnel.

Risks Related to the Combined Company Following the Mergers

The combined company expects to incur substantial expenses related to the Mergers.

The combined company expects to incur substantial expenses in connection with completing the Mergers and integrating the operations and systems of the Trust with those of Healthpeak. There are a number of factors that could affect the total amount or the timing of the combined company’s expenses relating to the completion of the Mergers and the combined company’s operations. Many of the expenses that will be incurred, by their nature, are difficult to estimate accurately at the present time. As a result, the expenses associated with the Mergers could, particularly in the near term, reduce the savings that the combined company expects to achieve from the elimination of duplicative expenses and the realization of economies of scale and cost savings related to the integration of the operations of the Trust following the completion of the Mergers.

Following the Mergers, the combined company may be unable to integrate the operations of Healthpeak and the Company successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame.

The Mergers involve the combination of two companies that currently operate as independent public companies and their respective operating partnerships. The combined company is expected to benefit from the elimination of duplicative costs associated with supporting a public company platform. However, the combined company will be required to devote significant management attention and resources to integrating the operations of Healthpeak and the Trust. Potential difficulties the combined company may encounter in the integration process include the following:

•the inability to successfully combine the operations of Healthpeak and the Trust, including, among other things, the integration of employees, customer and tenant records in a manner that permits the combined company to achieve the synergies anticipated to result from the Mergers, which would result in the anticipated benefits of the Mergers not being realized in the time frame currently anticipated or at all;

•the inability to dispose of former Company assets or operations that the combined company desires to dispose of;

•the complexities associated with managing the combined businesses out of different locations and integrating personnel from the two companies;

•the failure to retain key employees of either of the two companies;

•potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Mergers; and

•performance shortfalls as a result of the diversion of management’s attention caused by completing the Mergers and integrating the companies’ operations.

For all these reasons, it is possible that the integration process could result in the distraction of the combined company’s management, the disruption of the combined company’s ongoing business or inconsistencies in the combined company’s operations, services, standards, controls, procedures and policies, any of which could adversely affect the ability of the combined company to maintain relationships with tenants, property managers and employees or to achieve the anticipated benefits of the Mergers, or could otherwise adversely affect the business and financial results of the combined company.

The market price and trading volume of the combined company common stock may be volatile or may decline as a result of the Mergers.

The combined company’s common stock may experience significant price and volume fluctuations, and investors in shares of the combined company common stock may experience a decrease in the value of their shares, including decreases unrelated to the combined company’s operating performance or prospects. We cannot assure you that the market price of the combined company common stock will not fluctuate or decline significantly in the future.

Table of Contents

In addition, upon consummation of the Mergers, Healthpeak stockholders and the Trust shareholders will own interests in a combined company operating an expanded business with a different mix of properties, risks and liabilities. Current Healthpeak stockholders and the Trust shareholders may not wish to continue to invest in the combined company, or for other reasons may wish to dispose of some or all of their shares of the combined company common stock. If, following the Company Merger Effective Time, large amounts of the combined company common stock are sold, the price of the combined company common stock could decline.

The combined company may incur adverse tax consequences if Healthpeak or the Trust has failed or fails to qualify as a REIT for United States federal income tax purposes.

The Trust has operated in a manner that it believes has allowed it to qualify as a REIT for United States federal income tax purposes under the Code and intends to continue to do so through the closing date or the Company Merger Effective Time, respectively. The combined company intends to continue operating in such a manner following the Mergers. The closing of the Mergers is conditioned on the receipt by Healthpeak of an opinion of the Trust’s counsel to the effect that, commencing with the Trust’s taxable year ended December 31, 2015 and through the Company Merger Effective Time, the Trust has been organized and has operated in conformity with the requirements for qualification and taxation as a REIT under the Code, and on the receipt by the Trust of an opinion of Healthpeak’s counsel to the effect that, commencing with Healthpeak’s taxable year ended December 31, 2015, Healthpeak has been organized and operated in conformity with the requirements for qualification and taxation as a REIT under the Code, and Healthpeak’s proposed method of operation will enable it to continue to meet the requirements for qualification and taxation as a REIT under the Code for its taxable year that includes the Company Merger Effective Time and future taxable years. The foregoing REIT opinions, however, are limited to the factual representations provided by Healthpeak and the Trust to counsel and the assumptions set forth therein, and are not a guarantee that Healthpeak or the Trust has, in fact, qualified, or that the combined company will continue to qualify, as a REIT. Moreover, such opinions are not binding on the IRS, and neither Healthpeak nor the Trust has requested or plans to request a ruling from the IRS that it or the combined company qualifies as a REIT. Qualification as a REIT involves the application of highly technical and complex Code provisions for which there are only limited judicial and administrative interpretations. The complexity of these provisions and of the applicable regulations (as in effect from time to time) of the United States Department of the Treasury under the Code is greater in the case of a REIT, like Healthpeak and the Trust, that holds assets through a partnership. The determination of various factual matters and circumstances not entirely within Healthpeak’s and the Trust’s control may affect their ability to qualify as REITs.

In order to qualify as a REIT, each of Healthpeak and the Trust must satisfy a number of requirements, including requirements regarding the ownership of its stock and the composition of its gross income and assets. Also, a REIT must make distributions to stockholders annually equal, in the aggregate, to at least 90% of its net taxable income, determined without regard to the dividends paid deduction and excluding any net capital gains.

If Healthpeak or the Trust (or, following the Mergers, the combined company) loses its REIT status, or is determined to have lost its REIT status in a prior year, it will face material tax consequences that would substantially reduce its cash available for distribution, including cash available to pay dividends to its stockholders, because:

•it would be subject to United States federal income tax on its net income at regular corporate rates for the years it did not qualify for taxation as a REIT (and, for such years, would not be allowed a deduction for dividends paid to stockholders in computing its taxable income);

•it could be subject to a federal alternative minimum tax and possibly increased state and local taxes for such periods;

•unless it is entitled to relief under applicable statutory provisions, neither it nor any “successor” company (including, potentially, the combined company) could elect to be taxed as a REIT until the fifth taxable year following the year during which it was disqualified; and

•for five years following re-election of REIT status, upon a taxable disposition of an asset owned as of such re-election, it could be subject to corporate level tax with respect to any built-in gain inherent in such asset at the time of re-election.

Even if Healthpeak (or, following the Mergers, the combined company) retains its REIT status, if the Trust is determined to have lost its REIT status for a taxable year ending on or before the Company Merger, the Trust would be subject to adverse tax consequences similar to those described above. This could substantially reduce the combined company’s cash available for distribution, including cash available to pay dividends to its stockholders, because, assuming that the combined company otherwise maintains its REIT qualification:

•the combined company generally would be subject to corporate level tax with respect to the built-in gain on each asset of the Trust existing at the time of the Company Merger if the combined company were to dispose of the Trust asset during the five-year period following the Company Merger;

•the combined company would succeed to any earnings and profits accumulated by the Trust for taxable periods that it did not qualify as a REIT, and the combined company would have to pay a special dividend and/or employ applicable

Table of Contents

deficiency dividend procedures (including interest payments to the IRS) to eliminate such earnings and profits (or if the combined company does not timely distribute those earnings and profits, the combined company could fail to qualify as a REIT); and

•if the Trust incurred any unpaid tax liabilities prior to the Company Merger, those tax liabilities would be transferred to the combined company as a result of the Company Merger.

If there is an adjustment to the Trust’s taxable income or dividends paid deductions, the combined company could elect to use the deficiency dividend procedure in order to maintain the Trust’s REIT status. That deficiency dividend procedure could require the combined company to make significant distributions to its stockholders and to pay significant interest to the IRS.

As a result of all these factors, Healthpeak’s or the Trust’s (or, following the Mergers, the combined company’s) failure to qualify as a REIT could impair the combined company’s ability to expand its business and raise capital, and would materially adversely affect the value of its capital stock.

Item 2. Unregistered Sales of Equity Securities, ~~and~~ Use of Proceeds and Issuer Purchases of Equity Securities

Recent Sales of Unregistered Securities

From time to time the Operating Partnership issues OP Units to the Trust, as required by the Second Amended and Restated Agreement of Limited Partnership, ~~Agreement,~~ to reflect additional issuances of common shares by the Trust and to preserve equitable ownership ratios.

On July 3, 2023, we issued 25,000 common shares upon the redemption of OP Units held by an OP Unit holder in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

The following table sets forth information relating to repurchases of our common shares of beneficial interest and OP Units during the three months ended September 30, ~~2022:~~2023:

ISSUER PURCHASES OF EQUITY SECURITIES

Period (a) Total Number of Shares (or Units) Purchased (b) Average Price Paid per Share (or Unit) (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
July 1, 2022 - July 31, 2022 123,903 (1) $ 17.26 N/A N/A
August 1, 2022 - August 31, 2022 — — N/A N/A
September 1, 2022 - September 30, 2022 — — N/A N/A
Total 123,903 $ 17.26 — —


Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
July 1, 2023 - July 31, 2023	25,000	(1)	$	13.99	N/A	N/A
August 1, 2023 - August 31, 2023	—		—		N/A	N/A
September 1, 2023 - September 30, 2023	—		—		N/A	N/A
Total	25,000		$	13.99	—	—

(1)Represents OP Units redeemed by holders in exchange for ~~cash.~~common shares of the Company.

Item 5.Other Information

Rule 10b5-1 Trading Arrangements

On August 14, 2023, John T. Thomas, President and Chief Executive Officer of the Trust entered into a prearranged trading plan (the “10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 50,000 shares of common stock, subject to price and trading thresholds set under the plan. The 10b5-1 Plan begins on November 13, 2023, and expires when all of the shares are sold or on August 14, 2024, whichever occurs first.

Table of Contents

Item 6. Exhibits


~~Exhibit No.~~						~~Description~~
~~22.1~~						List of Subsidiary Issuers and Guaranteed Securities**
~~31.1~~						Certification of John T. Thomas, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust**
~~31.2~~						Certification of Jeffrey N. Theiler, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust**


~~32.1~~						Certification of John T. Thomas and Jeffrey N. Theiler, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) for Physicians Realty Trust**


~~101.INS~~						~~This instance document does not appear in the interactive data file because of XBRL tags are embedded within the inline XBRL document.~~
~~101.SCH~~						~~Inline XBRL Extension Schema Document (+)~~
~~101.CAL~~						~~Inline XBRL Taxonomy Extension Calculation Linkbase Document (+)~~
~~101.DEF~~						~~Inline XBRL Taxonomy Extension Definition Linkbase Document (+)~~
~~101.LAB~~						~~Inline XBRL Taxonomy Extension Label Linkbase Document (+)~~
~~101.PRE~~						~~Inline XBRL Taxonomy Extension Presentation Linkbase Document (+)~~
~~104~~						~~Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).~~


Exhibit No.		Description
2.1	(1)	Agreement and Plan of Merger dated as of October 29, 2023 among Healthpeak Properties, Inc., Alpine Sub, LLC , Alpine OP Sub, LLC , Physicians Realty Trust and Physicians Realty L.P.
3.1	(1)	Bylaws of Physicians Realty Trust, as amended through October 28, 2023
10.1	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and John T. Thomas
10.2	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and Jeffrey N. Theiler
10.3	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and D. Deeni Taylor
10.4	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and Mark D. Theine
10.5	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and John W. Lucey
10.6	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and Bradley D. Page
10.7	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and Daniel M. Klein
10.8	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and Laurie P. Becker
10.9	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and Amy M. Hall
10.10	(2)	Employment Agreement dated as of October 20, 2023, between the Trust and Mark Dukes
10.11		Form of Restricted Share Unit Award Agreement (Performance Units)**
10.12		Form of Restricted Share Award Agreement - Executives (Time Vesting)**
10.13		Form of Restricted Share Unit Award Agreement - Trustee (Time Vesting)**
10.14		Form of Restricted Share Unit Award Agreement - Trustee (In Lieu of Cash Retainer)**
10.15		Form of Restricted Share Award Agreement - Executives (Deferral)**
22.1		List of Subsidiary Issuers and Guaranteed Securities**
31.1		Certification of John T. Thomas, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust**
31.2		Certification of Jeffrey N. Theiler, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust**
32.1		Certification of John T. Thomas and Jeffrey N. Theiler, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) for Physicians Realty Trust**

101.INS		This instance document does not appear in the interactive data file because of XBRL tags are embedded within the inline XBRL document.
101.SCH		Inline XBRL Extension Schema Document (+)
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document (+)
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document (+)
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document (+)
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document (+)
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

** Filed herewith

(+) Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement for purposes of Section 11 or 12 of the Securities Act, is deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.

(1)Incorporated by reference to the Trust’s Current Report on Form 8-K filed with the SEC on October 30, 2023 (File No. 001-36007)

(2)Incorporated by reference to the Trust’s Current Report on Form 8-K filed with the SEC on October 20, 2023 (File No. 001-36007)

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			PHYSICIANS REALTY TRUST


Date: ~~November 4, 2022~~October 30, 2023			/s/ John T. Thomas
			John T. Thomas
			President and Chief Executive Officer
			(Principal Executive Officer)


Date: ~~November 4, 2022~~October 30, 2023			/s/ Jeffrey N. Theiler
			Jeffrey N. Theiler
			Executive Vice President and Chief Financial Officer
			(Principal Financial Officer)

4148


Total notional amount		$	36,050
Effective fixed interest rate	(1)	3.33		%
Effective date		10/31/2019
Maturity date		10/31/2024
Asset balance at September 30, 2022 (included in Other assets)		$	2,071
Liability balance at December 31, 2021 (included in Accrued expenses and other liabilities)		$	452